Resonant (RESN) 10-K 13 Mar 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Mar. 09, 2020	Jun. 28, 2019
Document and Entity Information
Entity Registrant Name	Resonant Inc
Entity Central Index Key	0001579910
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 51
Entity Common Stock, Shares Outstanding		52,447,128
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash and cash equivalents	$ 10,688,000	$ 4,394,000
Investments held-to-maturity	0	16,863,000
Accounts receivable	78,000	165,000
Prepaid expenses and other current assets	375,000	364,000
TOTAL CURRENT ASSETS	11,141,000	21,786,000
PROPERTY AND EQUIPMENT
Property and equipment	4,519,000	3,784,000
Less: Accumulated depreciation and amortization	(2,634,000)	(1,797,000)
Property and equipment, net	1,885,000	1,987,000
NONCURRENT ASSETS
Domain name and other intangibles, net	33,000	79,000
Patents, net	1,543,000	1,295,000
Restricted cash	150,000	211,000
Goodwill	831,000	817,000
Operating lease right-of-use assets	2,496,000
Other assets	68,000	69,000
TOTAL NONCURRENT ASSETS	5,121,000	2,471,000
TOTAL ASSETS	18,147,000	26,244,000
CURRENT LIABILITIES
Accounts payable	1,100,000	695,000
Accrued expenses	521,000	464,000
Accrued salaries and payroll related expenses	2,368,000	1,835,000
Deferred revenue	1,731,000	271,000
Operating lease liabilities, current	612,000
TOTAL CURRENT LIABILITIES	6,332,000	3,265,000
LONG-TERM LIABILITIES
Deferred rent		81,000
Operating lease liabilities, net of current portion	2,059,000	0
TOTAL LIABILITIES	8,391,000	3,346,000
Commitments and contingencies (Note 12)
STOCKHOLDERS’ EQUITY
Common stock, $0.001 par value, 100,000,000 authorized and 33,156,246 outstanding as of December 31, 2019 and 27,391,290 outstanding as of December 31, 2018	33,000	27,000
Preferred stock, $0.001 par value, 3,000,000 shares authorized and none outstanding as of December 31, 2019 and December 31, 2018	0	0
Additional paid-in capital	132,214,000	115,450,000
Accumulated other comprehensive income and (loss)	1,000	(15,000)
Accumulated deficit	(122,492,000)	(92,564,000)
TOTAL STOCKHOLDERS’ EQUITY	9,756,000	22,898,000
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 18,147,000	$ 26,244,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares outstanding (in shares)	33,156,246	27,391,290
Common stock, shares, issued (in shares)	33,156,246	27,391,290
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	3,000,000	3,000,000
Preferred stock, shares outstanding (in shares)	0	0

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
REVENUES	$ 735,000	$ 524,000
OPERATING EXPENSES
Research and development	18,854,000	14,271,000
Sales, marketing and administration	12,040,000	11,546,000
TOTAL OPERATING EXPENSES	30,894,000	25,817,000
NET OPERATING LOSS	(30,159,000)	(25,293,000)
OTHER INCOME (EXPENSE)
Interest and investment income	253,000	481,000
Other expense	(21,000)	(3,000)
TOTAL OTHER INCOME (EXPENSE)	232,000	478,000
LOSS BEFORE INCOME TAXES	(29,927,000)	(24,815,000)
Provision for income taxes	(1,000)	(1,000)
NET LOSS	(29,928,000)	(24,816,000)
Foreign currency translation adjustment, net of tax	16,000	(8,000)
COMPREHENSIVE LOSS	$ (29,912,000)	$ (24,824,000)
NET LOSS PER SHARE - BASIC AND DILUTED (in dollars per share)	$ (1.02)	$ (0.98)
Weighted average shares outstanding — basic and diluted (shares)	29,409,776	25,290,426

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income and (Loss)
Balance (in shares) at Dec. 31, 2017		19,511,276
Balance at Dec. 31, 2017	$ 20,648	$ 20	$ 88,447	$ (67,812)	$ (7)
Increase (Decrease) in Stockholders' Equity
Vesting of restricted stock units (in shares)		1,051,939
Vesting of restricted stock units	1	$ 1
Stock-based compensation	5,698		5,698
Sales of common stock, net of offering costs (in shares)		6,571,428
Sale of common stock, net of offering costs	21,189	$ 6	21,183
Exercises of warrants, cashless (in shares)		89,142
Common stock issued in exchange for warrants (in shares)		242,913
Common stock issued in exchange for warrants	260		260
Exercises of stock options (in shares)		4,692
Exercises of stock options	14		14
Repurchase and retirement of common stock (in shares)		(80,100)
Repurchase and retirement of common stock	(152)		(152)
Net loss	(24,816)			(24,816)
Foreign currency translation adjustment, net of tax	(8)				(8)
Balance at Dec. 31, 2018	$ 22,898	$ 27	115,450	(92,564)	(15)
Balance (in shares) at Dec. 31, 2018	27,391,290	27,391,290
Increase (Decrease) in Stockholders' Equity
Vesting of restricted stock units (in shares)		1,317,587
Vesting of restricted stock units	$ 1	$ 1
Stock-based compensation	5,463		5,463
Sales of common stock, net of offering costs (in shares)		3,960,560
Sale of common stock, net of offering costs	9,919	$ 4	9,915
Exercises of warrants, cashless (in shares)		486,809
Common stock issued in exchange for warrants	$ 1,387	$ 1	1,386
Exercises of stock options (in shares)	0
Repurchase and retirement of common stock (in shares)		0
Net loss	$ (29,928)			(29,928)
Foreign currency translation adjustment, net of tax	16				16
Balance at Dec. 31, 2019	$ 9,756	$ 33	$ 132,214	$ (122,492)	$ 1
Balance (in shares) at Dec. 31, 2019	33,156,246	33,156,246

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (29,928,000)	$ (24,816,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	985,000	840,000
Stock-based compensation	5,806,000	5,262,000
Non-cash interest and investment income	0	(153,000)
Non-cash patent write-off	145,000	96,000
Non-cash loss on disposal of assets	4,000	(7,000)
Right-of-use asset amortization	586,000	0
Changes in assets and liabilities:
Accounts receivable	87,000	(115,000)
Prepaids and other current assets	(10,000)	239,000
Other assets	1,000	(50,000)
Deferred taxes	0	(1,000)
Accounts payable	249,000	107,000
Accrued expenses	210,000	(66,000)
Accrued salaries and payroll related expenses	191,000	334,000
Operating lease liabilities	(492,000)
Deferred revenue	1,460,000	128,000
Deferred rent	0	71,000
Net cash used in operating activities	(20,706,000)	(18,131,000)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of property and equipment	0	16,000
Purchases of property and equipment	(806,000)	(1,285,000)
Expenditures for patents and domain names	(424,000)	(219,000)
Redemptions of investments held-to-maturity	29,295,000	39,590,000
Purchases of investments held-to-maturity	(12,432,000)	(56,300,000)
Net cash provided by (used in) investing activities	15,633,000	(18,198,000)
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from the sale of common stock from private placement offerings	9,919,000	0
Net proceeds from the sale of common stock from underwritten public offering	0	21,190,000
Acquisition of common stock under repurchase program	0	(152,000)
Proceeds from exercises of warrants	1,387,000	260,000
Proceeds from exercises of stock options	0	14,000
Net cash provided by financing activities	11,306,000	21,312,000
Effects of currency translation on cash, cash equivalents and restricted cash	0	(2,000)
NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	6,233,000	(15,019,000)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of year	4,605,000	19,624,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — End of year	10,838,000	4,605,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for taxes	1,000	3,000
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES
Common stock issued in settlement of accrued salaries and payroll related expenses	342,000	436,000
Property and equipment included in accounts payable	206,000	95,000
Property and equipment included in accrued liabilities	159,000	305,000
Patents included in accounts payable	83,000	39,000
Patents included in accounts payable	0	6,000
Total cash, cash equivalents and restricted cash	$ 10,838,000	$ 4,605,000

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	ORGANIZATION AND DESCRIPTION OF BUSINESS Overview Resonant Inc. is a late-stage development company located in Goleta, California. We were incorporated in Delaware in January 2012 as a wholly owned subsidiary of Superconductor Technologies Inc., or STI. Resonant LLC, a limited liability company, was formed in California in May 2012. We changed our form of ownership from a limited liability company to a corporation in an exchange transaction in June 2013, when we commenced business. We are the successor of Resonant LLC. We completed our initial public offering, or IPO, on May 29, 2014. On July 6, 2016 we acquired all of the issued and outstanding capital stock of GVR Trade S.A, or GVR. GVR is a wholly owned subsidiary of Resonant Inc. Using our innovative software platform we have developed an IP portfolio of more than 200 patents filed or issued, with more than 40 filed or issued targeting XBAR technology, including application to 5G. In addition, with continued requirements for increasing numbers of filter designs our innovative software platform addresses the need for increased designer efficiency, reduced time to market and lower unit costs in the designs of filters for radio frequency, or RF, front-ends for the mobile device industry. The RF front-end, or RFFE, is the circuitry in a mobile device responsible for analog signal processing and is located between the device’s antenna and its digital circuitry. The software platform we continue to develop is based on fundamentally new technology that we call Infinite Synthesized Networks®, or ISN®, to configure and connect resonators, the building blocks of RF filters. Filters are a critical component of the RF front-end used to select desired radio frequency signals and reject unwanted signals. We believe licensing our designs is the most direct and effective means of validating our ISN ® platform and related IP libraries. Our target customers make part or all of the RFFE. We intend to retain ownership of our designs, and we expect to be compensated through license fees and royalties based on sales of RFFE filters that incorporate our designs. Capital Resources and Liquidity As of December 31, 2019, our accumulated deficit totaled $122.5 million . During 2019 our net loss totaled $29.9 million and we used $21.9 million of cash and investments for operating activities, the purchase of property and equipment and expenditures for patents. To date we have not generated significant revenues to enable profitability. We expect to continue to incur significant losses. These factors raise substantial doubt regarding our ability to continue as a going concern. At December 31, 2019 we had cash and cash equivalents of $10.7 million . In February 2020 we completed a common stock equity offering that netted $26.3 million . In the absence of a significant revenue increase these cash resources will provide sufficient funding into early 2021 . We are subject to the risks and uncertainties associated with a new business. Our continuance as a going concern is dependent on future profitability. We are actively pursuing expanding our technology portfolio, increasing our revenue opportunities by completing deliverables under current contracts and entering into new prepaid and paid up royalty arrangements, and efficiently managing operations and exploring cost saving opportunities. We may not be successful in these efforts. We may need to seek to raise additional capital from the sale of equity securities or incurrence of indebtedness. There can be no assurance that additional financing will be available to us on acceptable terms, or at all in which case we might be forced to make substantial reductions in our operating expenses which could adversely affect our ability to implement our business plan and ultimately our viability as a company. The accompanying consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Use of Estimates —The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. Significant estimates made in preparing these financial statements include (a) assumptions to calculate the fair values of financial instruments, warrants and equity instruments and other liabilities and the deferred tax asset valuation allowance and (b) the useful lives for depreciable and amortizable assets. Actual results could differ from those estimates. In the opinion of management, all adjustments, including normal recurring accruals considered necessary for a fair presentation, have been included. Consolidation - The accompanying financial statements include the accounts of the Company and its wholly-owned subsidiary, GVR. All significant intercompany balances and transactions have been eliminated. Cash and Cash Equivalents —We consider all liquid instruments purchased with a maturity of three months or less to be cash equivalents. Concentration of Credit Risk —We maintain bank accounts at one U.S. financial institution. The U.S. bank accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per account owner. GVR, our wholly owned Swiss-based subsidiary maintains checking accounts at one major national financial institution. Additionally, we maintain a checking account with a very minimal balance at one bank in South Korea, which is used to fund payroll and rent in South Korea. Management believes we are not exposed to significant credit risk due to the financial position of the depository institutions in which our deposits are held. Restricted Cash —Restricted cash at December 31, 2018 and 2019 consists of a pledged mutual fund account which is held as collateral against a letter of credit issued in May 2018 in connection with the lease of our corporate headquarters. The terms of the letter of credit allow for a step-down of $50,000 annually upon performance of certain events, primarily no late or defaulted payments. See also Note 12- Commitments and Contingencies, for further details. Investments —Securities held-to-maturity: Management determines the appropriate classification of debt securities at the time of purchase and reevaluates such designation as of each balance sheet date. Investment/debt securities are classified as held-to-maturity when we have the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest method. Such amortization is included in investment income. Interest on securities classified as held-to-maturity is included in interest and investment income. When the fair value of an investment instrument classified as held-to-maturity is less than its amortized cost, management assesses whether or not: (i) we have the intent to sell the instrument or (ii) it is more likely than not that we will be required to sell the instrument before its anticipated recovery. If either of these conditions is met, we must recognize an other-than-temporary impairment for the difference between the instrument’s amortized cost basis and its fair value, and include such amounts in other income (expense). For investment instruments that do not meet the above criteria and are not expected to be recovered at the amortized cost basis, the instrument is considered other-than-temporarily impaired. For these instruments, we separate the total impairment into the credit loss component and the amount of the loss related to other factors. In order to determine the amount of the credit loss, we calculate the recovery value by performing a discounted cash flow analysis based on the current cash flows and future cash flows management expects to recover. The discount rate is the effective interest rate implicit in the underlying instrument. The amount of the total other-than-temporary impairment related to credit loss is recognized in earnings and is included in other income (expense). The amount of the total other-than-temporary impairment related to other factors is recognized in other comprehensive income. For investment instruments that have other-than-temporary impairment recognized through earnings, if through subsequent evaluation there is a significant increase in the cash flow expected, the difference between the amortized cost basis and the cash flows expected to be collected is accreted as interest income. Fair Value of Financial Instruments —We measure certain financial assets and liabilities at fair value based on the exit price notion, or price that would be received for an asset or paid to transfer a liability, in an orderly transaction between the market participants at the measurement date. The carrying amounts of our financial instruments, including cash equivalents, restricted cash, accounts receivable, investments held-to-maturity, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. Accounts Receivable —Trade accounts receivable are stated net of allowances for doubtful accounts. Management estimates the allowance for doubtful accounts based on review and analysis of specific customer balances that may not be collectible, customer payment history and any other customer-specific information that may impact collectability of the receivable. Accounts are considered for write-off when they become past due and when it is determined that the probability of collection is remote. The was no allowance for doubtful accounts at December 31, 2018 and December 31, 2019. Property and Equipment —Property and equipment consists of leasehold improvements associated with our corporate offices, software purchased during the normal course of business, equipment and office furniture and fixtures, all of which are recorded at cost. Depreciation and amortization is recorded using the straight-line method over the respective useful lives of the assets ranging from three to five years . Leasehold improvements are amortized over the shorter of lease term or useful life. Long-lived assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. Intangible Assets, net —Intangible assets are recorded at cost and amortized over the useful life. In the case of business combinations, intangible assets are recorded at fair value. At December 31, 2018 and December 31, 2019 , intangible assets, net, includes patents and a domain name and other intangible assets purchased as part of our acquisition of GVR, including customer relationships, technology and a trademark. Intangible assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. In certain cases, patents may expire or be abandoned as we no longer plan to pursue them. In such cases we write off the capitalized patent costs as patent abandonment costs which are included in research and development expenses. Goodwill— Goodwill represents the difference between the price paid to acquire GVR and the fair value of the assets acquired, net of assumed liabilities. We review goodwill for impairment annually and whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. As of January 1, 2019, we have adopted ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , which simplifies the accounting for goodwill impairments by eliminating step 2 from the goodwill impairment test. Revenue Recognition —Revenue is recognized upon the transfer of control of promised goods or services to the customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue consists primarily of upfront non-refundable fees received in connection with filter design projects with customers and royalties. Our performance obligation is to design a licensable filter in accordance with customer specifications. The license of the completed design is considered part of this performance obligation as the design and licensing of the filter are highly interdependent. We recognize revenue over the course of the design development phase as our customers are able to benefit from our design services as they are provided, primarily by marketing the in-process design to their customers. We recognize revenue from our design services based on efforts expended to date. At the end of each reporting period, we reassess our measure of progress and adjust revenue when appropriate. We record the expenses related to these projects in the periods incurred and they are generally included in research and development expense. In most cases, upfront non-refundable payments related to design development are recognized over a period of 12 months to 18 months . Contracts generally include upfront non-refundable fees, intended to support our initial engineering product development efforts, and may include milestone payments based upon the successful completion of certain deliverables. Milestone payments represent variable consideration, and we use the "most likely amount" approach to determine the amount we ultimately expect to receive. At contract inception, we assess the likelihood of achieving milestones to estimate the total consideration we believe we will receive for our services. Upon completion of design services, our customers retain a license over the completed design. The license will typically last for a minimum of two years, and in many cases for the life of the design. Royalties are sales-based, and we recognize royalty revenue upon shipment, by our customer, of products that include our licensed design. Payment is generally due within 30 days. We apply the practical expedients available in ASC 606 to not disclose information about 1) remaining performance obligations that have original expected durations of one year or less and 2) variable consideration that is a sales-based or usage-based royalty. Research and Development —Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with ASC Topic 730-10, Research and Development . Operating Leases —We lease office space and research facilities under operating leases. Certain lease agreements contain free or escalating rent payment provisions. As of January 1, 2019, we have adopted ASU No. 2016-02, Leases (Topic 842) as well as other clarifying and practical updates issued under Leases (Topic 842) applicable to us. We determine if an arrangement is a lease at lease inception. Operating leases are included in right-of-use (“ROU”) lease assets, other current liabilities (current portion of lease obligations), and long term lease obligations on our balance sheets. ROU lease assets represent our right to use an underlying asset for the lease term and lease obligations represent our obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use an incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset also includes any lease payments made and excludes lease incentives. We evaluate renewal options at lease inception and on an ongoing basis, and include renewal options which we are reasonably certain to exercise in our expected lease term when classifying leases and measuring lease liabilities. We allocate the consideration between lease and nonlease components and exclude nonlease components from our recognized lease assets and liabilities. See also Recent Accounting Pronouncements and Note 10 - Leases. Minimum lease payments, including scheduled rent increases, are recognized as lease expenses on a straight-line basis over the applicable lease term. We recognize lease expenses within research and development and sales, marketing and administration expenses on a straight-line basis over the lease term. We are not party to any leases for which we are the lessor. Stock-Based Compensation —We account for employee stock options in accordance with ASC Topic 718, Compensation-Stock Compensation . We use the Black-Scholes option valuation model for estimating fair value at the date of grant. We account for restricted stock units issued at fair value, based on the market price of our stock on the date of grant, net of estimated forfeitures. Compensation expense is recognized for the portion of the award that is ultimately expected to vest over the period during which the recipient renders the required services to the Company generally using the straight-line single option method. In the case of award modifications, we account for the modification in accordance with ASU No.2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting , whereby we recognize the effect of the modification in the period the award is modified. As of January 1, 2019, we adopted ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting , which aligns the accounting of share-based payment awards issued to employees and non-employees. The adoption did not materially impact our condensed consolidated financial statements. Stock-based compensation expense is included in research and development expenses and general and administrative expenses. Earnings Per Share, or EPS —EPS is computed in accordance with ASC Topic 260, Earnings per Share , and is calculated using the weighted average number of common shares outstanding during each period. Diluted EPS assumes the conversion, exercise or issuance of all potential common stock equivalents unless the effect is to reduce a loss or increase the income per share. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options (using the treasury stock method), the exercise of warrants (using the if-converted method) and the vesting of restricted stock unit awards. Income Taxes —We account for income taxes in accordance with ASC Topic 740, Income Taxes , or ASC 740, which requires the recognition of deferred tax assets and liabilities for the future consequences of events that have been recognized in our consolidated financial statements or tax returns. The measurement of the deferred items is based on enacted tax laws. In the event the future consequences of differences between financial reporting bases and the tax bases of our assets and liabilities result in a deferred tax asset, ASC 740 requires an evaluation of the probability of being able to realize the future benefits indicated by such asset. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion or the entire deferred tax asset will not be realized. As part of the process of preparing our consolidated financial statements, we are required to estimate our income tax expense in each of the jurisdictions in which we operate. We also assess temporary differences resulting from differing treatment of items for tax and accounting differences. We record a valuation allowance to reduce the deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. For the period when we were organized as a limited liability company, we were treated as a partnership for federal and state income tax purposes under the entity classification domestic default rules. As of December 31, 2019 and December 31, 2018, no liability for unrecognized tax benefits was required to be reported. We recognize interest and penalties related to income tax matters in income taxes, and there were none for the years ended December 31, 2019 and December 31, 2018, respectively. We have filed, or are in the process of filing, tax returns that are subject to audit by the respective tax authorities. Although the ultimate outcome is unknown, we believe that any adjustments that may result from tax return audits are not likely to have a material, adverse effect on our consolidated results of operations, financial position or cash flows. Reclassifications —Certain amounts in the consolidated balance sheet for the year ended December 31, 2018 have been reclassified to conform to the current year presentation. Foreign Currency Translation —The Swiss Franc has been determined to be the functional currency for the net assets of our Swiss-based subsidiary. We translate the assets and liabilities to U.S. dollars at each reporting period using exchange rates in effect at the balance sheet date and record the effects of the foreign currency translation in accumulated other comprehensive loss in shareholders' equity. We translate the income and expenses to U.S. dollars at each reporting period using the average exchange rate in effect for the period and record the effects of the foreign currency translation as other comprehensive income (loss) in the condensed consolidated statements of comprehensive loss. Gains and losses resulting from foreign currency transactions are included in net loss in the condensed consolidated statements of comprehensive loss. Recent Accounting Pronouncements Leases— In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , which, among other things required the recognition of lease assets and lease liabilities on the balance sheet for substantially all leases, including operating leases. Expanded disclosures with additional qualitative and quantitative information are also required. ASU 2016-02 and its amendments are effective for interim and annual reporting periods beginning after December 15, 2018 and early adoption was permitted. The standard allows for two methods of transition, one of which allows for the guidance to be applied to all leases existing at the adoption date with a cumulative effect adjustment to the opening balance sheet of retained earnings. Under this transition approach, comparative periods presented in the financial statements remain under legacy lease guidance. We adopted the standard, as well as certain practical expedients included therein, utilizing the optional transition method as of January 1, 2019. Therefore, we have not restated comparative periods in our 2019 financial statements and prior periods are not included in our leased properties footnote. The adoption did not have any cumulative adjustment impact on retained earnings. We elected the package of practical expedients permitted under the transition guidance, which allowed us to carry forward our historical assessments of: (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs. In addition, we did not elect the hindsight practical expedient to determine the reasonably certain lease term for existing leases. We also elected a policy of not recording leases on our condensed consolidated balance sheets when the leases have a term of 12 months or less and we are not reasonably certain to elect an option to purchase the leased asset. The adoption of the standard on January 1, 2019 caused us to recognize approximately $3.0 million in each, right-of-use assets and lease liabilities, in our condensed consolidated financial statements. The right-of-use asset balance reflects the impact of other liability amounts, specifically deferred rent, that has been effectively reclassified. The standard did not materially impact consolidated net income or liquidity.

REVENUE RECOGNITION

REVENUE RECOGNITION	12 Months Ended
	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
REVENUE RECOGNITION	REVENUE RECOGNITION We record contract assets and contract liabilities in connection with revenue recognized for filter design projects. Contract Assets - Contract assets, other than accounts receivable, consist of unbilled revenue and generally arise when revenue is recognized on a contract whose transaction price includes an estimate of variable consideration from milestone payments. We do not have material amounts of contract assets as we have relatively few contracts, only modest design service fees and a small number of contracts containing milestone payments. Contract asset balances are included in prepaid expenses and other current assets in our condensed consolidated balance sheets. Contract Liabilities - Our contract liabilities consist of customer deposits and deferred revenue. We classify contract liabilities as current or noncurrent based on the timing of when we expect to recognize revenue. Generally, our contract liabilities are expected to be recognized in one year or less. Customer deposits and deferred revenue are separately stated in our condensed consolidated balance sheets. Summary of changes in contract assets and liabilities for the years ended December 31, 2019 and 2018: 2019 2018 Contract assets Contract assets, beginning $ 36,000 $ 67,000 Contract assets at beginning of year transferred to accounts receivable (36,000 ) (43,000 ) Reversal of contract assets due to changes in transaction price (8,000 ) (24,000 ) Contract assets recorded on contracts during the period 8,000 36,000 Contract assets, ending $ — $ 36,000 Contract liabilities Contract liabilities, beginning $ 271,000 $ 146,000 Recognition of revenue included in beginning of year contract liabilities (209,000 ) (138,000 ) Contract liabilities, net of revenue recognized on contracts during the period 1,669,000 263,000 Contract liabilities, ending $ 1,731,000 $ 271,000 The following table presents our disaggregated revenue by geographic region: 2019 2018 Revenue by geographic region: United States $ 735,000 $ 447,000 Switzerland — 77,000 Total revenue $ 735,000 $ 524,000 Effective September 30, 2019 we entered into a collaboration and license agreement with Murata Manufacturing Co., Ltd. Pursuant to the collaboration agreement, we have agreed with Murata to collaborate on the development of proprietary circuit designs using our XBAR® technology, and we licensed to Murata rights for products in four specific radio frequencies, or bands. Murata has agreed to pay us up to an aggregate of $9.0 million as pre-paid royalties and other fees for the licensed designs and certain other intellectual property developed in the collaboration, payable in installments over a multi-year development period, with each installment conditional upon our achievement of certain milestones and deliverables acceptable to Murata in its discretion. Murata may terminate the collaboration agreement at any time upon thirty ( 30 ) days prior written notice to us. Murata’s rights to our XBAR® technology are exclusive for a period of 30 months , through March 2022, during which period we may not grant to any third party the right to develop, make, have made, use, sell, offer for sale or import any filter or resonator produced through the use of the XBAR® technology for use in mobile communication devices. Under the collaboration agreement, the first of payment of $2.0 million was due to us, and was recorded initially in accounts receivable with the offset to deferred revenue. Payment was received on October 11, 2019. In accordance with the guidance of ASC 606, we are required to evaluate the variable consideration within the contract, primarily the milestone payments, and assess the likelihood of achievement in determining our transaction price. Additionally, we must assess whether the variable consideration is constrained and whether recording such variable revenue may result in a significant reversal of revenue due to uncertainties. We continue to evaluate variable consideration for inclusion in the transaction price, and ultimately the revenue recognized, at each reporting period. We recognize revenue for the Murata contract over the estimated design development period, based on the level of effort expended over total expected costs, as the services are performed. For the period ended December 31, 2019, we have determined that the milestone payments due upon achievement of certain performance criteria are constrained and are thus not included in the transaction price. Therefore, revenue related to those milestone payments has not been recognized. Revenue recognition related to each milestone payment will commence once the constraint is lifted.

INVESTMENTS HELD-TO-MATURITY

INVESTMENTS HELD-TO-MATURITY	12 Months Ended
	Dec. 31, 2019
Investments [Abstract]
INVESTMENTS HELD-TO-MATURITY	INVESTMENTS HELD-TO-MATURITY We classify investments as held-to-maturity when we have the positive intent and ability to hold the securities to maturity. During 2018, we invested in U.S. Treasury bills, commercial papers and a certificate of deposit that were classified as investments held-to-maturity. As of December 31, 2018, both amortized cost value and fair value were $16.9 million with zero unrealized gain or loss. During 2018, U.S. Treasury bills totaling $25.0 million matured in April 2018 and certain commercial papers totaling $14.6 million also matured during the year. All investments as of December 31, 2018 matured in January 2019. During 2019 , we invested in commercial papers and certificates of deposit that were classified as investments held-to-maturity. As of December 31, 2019, all of our investments held-to-maturity had matured and we had no investments classified as held-to-maturity. We recorded interest and investment income of $253,000 and $481,000 for the years ended December 31, 2019 and 2018, respectively, associated with our cash and investment accounts. We did not recognize an other-than-temporary impairment or a comprehensive gain or loss for the years ended December 31, 2019 and 2018.

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET	PROPERTY AND EQUIPMENT, NET Property and equipment, net, consists of the following as of December 31, 2019 and 2018: 2019 2018 Cost: Computers, peripheral and scientific equipment $ 1,654,000 $ 1,350,000 Software 2,131,000 1,749,000 Leasehold improvements 310,000 294,000 Office furniture and equipment 424,000 391,000 4,519,000 3,784,000 Less: Accumulated depreciation and amortization (2,634,000 ) (1,797,000 ) Property and equipment, net $ 1,885,000 $ 1,987,000 Depreciation for the years ended December 31, 2019 and December 31, 2018 was $870,000 and $704,000 , respectively. Cost basis of assets disposed for the years ended December 31, 2019 and December 31, 2018 was $31,000 and $773,000 , respectively. The disposals in 2018 were primarily a result of relocating our corporate offices and writing off the fully amortized leasehold improvements related to our former office.

INTANGIBLE ASSETS, NET, AND GOO

INTANGIBLE ASSETS, NET, AND GOODWILL	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS, NET, AND GOODWILL	INTANGIBLE ASSETS, NET, AND GOODWILL Intangible assets include patents, domain name and other intangibles purchased from GVR, including customer relationships, technology and a trademark. Certain patents were acquired from STI as a result of an asset contribution and were recorded at their carryover basis. The fair value of the patents remained substantially the same as their carrying value at the exchange date. In addition, we acquired other patents and the domain name www.resonant.com through the normal course of business. Intangibles acquired as part of the purchase of GVR were initially recorded at their fair value. Issued patents are amortized over their approximate useful life of 17 years, or 20 years in the case of new patents, once they are approved by their respective regulatory agency. For the patents acquired from STI, we are amortizing them over the remaining useful life of 1 to 11 years as of December 31, 2019 . The domain name is amortized over the approximate useful life of 10 years. The other intangibles acquired from GVR are amortized over their useful life of three to five years. Intangible assets, net, consists of the following as of December 31, 2019 and 2018: 2019 2018 Cost: Patents $ 1,801,000 $ 1,507,000 Domain name 22,000 22,000 Client Base (1) 144,000 142,000 Trademark (1) 18,000 17,000 Backlog (1) 13,000 13,000 Technology 77,000 77,000 2,075,000 1,778,000 Less: Accumulated amortization (499,000 ) (404,000 ) Intangible assets, net $ 1,576,000 $ 1,374,000 (1) Includes the impact of foreign currency translation. The total impact at December 31, 2018 was $1,000 and there was no impact at December 31, 2019 . During the year ended December 31, 2019 and 2018, we wrote-off $145,000 and $96,000 , respectively, of patents we are no longer pursuing. The write-offs are included in research and development expense. There were no impairments to any other intangibles. Amortization of intangible assets was $115,000 and $136,000 for the years ended December 31, 2019 and 2018, respectively. The following table summarizes the estimated amortization expense relating to the intangible assets as of December 31, 2019 : Years ending December 31, 2020 $ 94,000 2021 85,000 2022 75,000 2023 72,000 2024 71,000 2025 and thereafter 554,000 Total amortization expense $ 951,000 Goodwill represents the excess of the purchase price over the fair value of the net assets acquired from GVR Trade. Goodwill is not amortized, but is subject to impairment tests on at least an annual basis and whenever circumstances suggest that goodwill may be impaired. The following table summarizes goodwill arising from the acquisition of GVR Trade: Goodwill Balance at January 1, 2018 $ 824,000 Effect of currency translation (7,000 ) Balance at December 31, 2018 $ 817,000 Effect of currency translation 14,000 Balance at December 31, 2019 $ 831,000

WARRANTS

WARRANTS	12 Months Ended
	Dec. 31, 2019
Warrants and Rights Note Disclosure [Abstract]
WARRANTS	WARRANTS From time to time, we have issued warrants to purchase shares of common stock. These warrants have been issued in connection with financing transactions and for consulting services. Our warrants are subject to standard anti-dilution provisions applicable to shares of our common stock. In January 2018, we entered into an agreement with our founders to exchange warrants to purchase an aggregate of 249,999 shares of our common stock, with an exercise price of $0.20 per share, for an amount of shares that would equal the number of shares they would have received if exercised under a cashless exercise. The effect of exchanging the warrants for shares of our common stock was considered a modification of the award which required us to record expense for the excess of the fair value of the common stock issued over the fair value of the exchanged warrants. On the date of the exchange the fair value of the warrants was determined to be $1.6 million and the fair value of the shares of common stock issued were $1.6 million . There was a difference in fair value of $2,000 which was recorded to sales, marketing and administration expenses during the year ended December 31, 2018. No expense was recorded for the year ended December 31, 2019. Consulting Warrant, Financing Warrant and Underwriting Warrant Upon consummation of our Senior Convertible Note financing in June 2013, we issued warrants for business consulting services provided by MDB Capital Group, LLC, or MDB. We issued a 7 -year warrant to purchase 222,222 shares of our common stock at an exercise price of $0.01 per share, which we refer to as the Consulting Warrant. The Consulting Warrant is exercisable six months after the completion of our initial public offering, or IPO, in 2014 and expires June 17, 2020 . In addition, for placement agent services provided by MDB in connection with our Senior Convertible Note financing, we issued to MDB a 7 -year warrant to purchase 208,763 shares of our common stock at an exercise price of $3.35 per share, which we refer to as the Financing Warrant. The Financing Warrant is exercisable six months after the completion of our IPO and expires June 17, 2020 . In connection with the closing of our IPO, we also issued a third warrant to MDB related to their role as the sole underwriter for our IPO, which we refer to as the Underwriting Warrant. We issued them a 5 -year warrant to purchase 310,500 shares of common stock at an exercise price of $7.50 per share. The warrant was not exercisable until November 24, 2014 ( 180 -days from the date of the underwriting agreement) and expired May 28, 2019 . Private Placement Warrants - 2016 In April 2016 , we issued warrants to purchase 1,996,880 shares of our common stock at an exercise price of $2.86 in connection with our private placement sale of 1,996,880 shares of common stock. The warrants were exercisable for a period commencing October 2016 and expired on April 25, 2019 . We also issued to the placement agents in the financing, warrants to purchase an aggregate of 99,844 shares of our common stock at an exercise price of $2.86 for a period commencing 6 months and ending 36 months after the closing. We refer to these warrants as Private Placement Warrants - 2016 . In December 2017 , we entered into Warrant Exercise Agreements with certain holders of Private Placement Warrants - 2016 to induce the exercise of 836,780 warrants in full. Pursuant to the agreements, the warrant holders exercised in full the warrants and purchased an aggregate of 836,780 shares of our common stock at an exercise price of $2.86 per share, for an aggregate exercise price of approximately $2.4 million and we paid the warrant holders aggregated inducement fees of approximately $239,000 , which resulted in net proceeds to us of $2.2 million . All remaining unexercised warrants as of April 25, 2019 expired. Underwriting Warrants - Public Offering 2016 In September 2016 , we issued warrants to purchase 135,750 shares of our common stock at an exercise price of $4.25 to the underwriter of our public offering of 2,715,000 shares of common stock. The warrants were exercisable for a 2 year period commencing September 9, 2017 . We refer to these warrants as Underwriting Warrants - Public Offering 2016. All remaining unexercised warrants as of September 9, 2019 expired. Private Placement Warrants - September 2017 In September and October 2017, we issued warrants to purchase an aggregate of 1,976,919 shares of our common stock at an exercise price of $4.85 in connection with our private placement sale of 1,976,919 shares of common stock. The sale was completed in two tranches with the first tranche, which closed on September 28, 2017 , including 1,745,581 warrants, and the second tranche, which closed on October 2, 2017 , including 231,338 warrants. The warrants are exercisable for a period commencing 6 months after the closing of the financing and expire on September 28, 2020. Collectively, we refer to these warrants as Private Placement Warrants - September 2017. Placement Agent Warrants - 2017 In addition to the Private Placement Warrants - September 2017 issued in connection with our private placement sale of 1,976,919 shares of our common stock, we also issued to the placement agent, warrants to purchase a total of 98,846 shares of our common stock at an exercise price of $4.85 per share. Upon closing of the first tranche on September 28, 2017, we issued 87,279 warrants, and upon closing the second tranche, we issued 11,567 warrants. The warrants are exercisable for a period commencing 6 months after the closing of the financing and expire on September 28, 2020 . Collectively, we refer to these warrants as Placement Agent Warrants - 2017. A roll-forward of warrant activity from January 1, 2018 to December 31, 2018 is shown in the following table: Issued and Warrants Issued and Bridge Warrants 249,999 (249,999 ) (1) — Consulting Warrant 12,223 (5,556 ) (2) 6,667 Financing Warrant 62,530 — 62,530 Underwriting Warrant 310,500 — 310,500 IR Consulting Warrant 6,000 (6,000 ) (3) — Private Placement Warrants - 2016 891,063 (73,000 ) (4) 818,063 Underwriting Warrants - Public Offering 2016 122,175 — 122,175 Private Placement Warrants - September 2017 1,976,919 (10,600 ) (5) 1,966,319 Placement Agent Warrants - 2017 98,846 — 98,846 3,730,255 (345,155 ) 3,385,100 (1) During the year ended December 31, 2018, there were 249,999 warrants that were exchanged for 242,913 shares of common stock in an exchange transaction where the warrant holders exchanged the warrants for the same number of shares they would have been entitled to in a cashless exercise. (2) During the year ended December 31, 2018, there were 5,556 warrants that were exercised through a cashless exercise, which netted 5,542 shares being issued. (3) During the year ended December 31, 2018, 6,000 warrants expired. (4) During the year ended December 31, 2018, there were 73,000 warrants exercised for cash. (5) During the year ended December 31, 2018, there were 10,600 warrants exercised for cash. A roll-forward of warrant activity from January 1, 2019 to December 31, 2019 is shown in the following table: Exercise Price Expiration Date Issued and Warrants Issued and Consulting Warrant $0.01 6/17/2020 6,667 — 6,667 Financing Warrant $3.35 6/17/2020 62,530 — 62,530 Underwriting Warrant $7.50 5/28/2019 310,500 (310,500 ) (1) — Private Placement Warrants - 2016 $2.86 4/25/2019 818,063 (818,063 ) (2) — Underwriting Warrants - Public Offering 2016 $4.25 9/9/2019 122,175 (122,175 ) (3) — Private Placement Warrants - September 2017 $4.85 9/28/2020 1,966,319 — 1,966,319 Placement Agent Warrants - 2017 $4.85 9/28/2020 98,846 — 98,846 3,385,100 (1,250,738 ) 2,134,362 (1) During the year ended December 31, 2019, 310,500 warrants expired. (2) During the year ended December 31, 2019, there were 485,000 warrants exercised for cash, including 335,000 warrants exercised by our significant shareholder, Park City Capital. Additionally, there were 44,928 warrants that were exercised through a cashless exercise which netted 1,809 shares being issued and 288,135 warrants that expired. (3) During the year ended December 31, 2019, 122,175 warrants expired.

STOCKHOLDERS_ EQUITY AND EARNIN

STOCKHOLDERS’ EQUITY AND EARNINGS PER SHARE	12 Months Ended
	Dec. 31, 2019
Stockholders' Equity Note [Abstract]
STOCKHOLDERS’ EQUITY AND EARNINGS PER SHARE	STOCKHOLDERS’ EQUITY AND EARNINGS PER SHARE Common Stock Pursuant to our amended and restated certificate of incorporation, we are authorized to issue 100,000,000 shares of common stock. Holders of our common stock are entitled to dividends as and when declared by the board of directors, subject to rights and holders of all classes of stock outstanding having priority rights to dividends. There have been no dividends declared to date. Each share of common stock is entitled to one vote. On March 27, 2018, we completed the sale of 5,714,286 shares of common stock at a price of $3.50 per share in an underwritten public offering. Gross proceeds were $20.0 million with net proceeds of $18.4 million after deducting underwriter fees and offering expenses. The shares were issued pursuant to a shelf registration statement that we filed with the SEC, which became effective in May 2016. On April 6, 2018, following exercise by the underwriter of its overallotment option, we sold an additional 857,142 shares at a price of $3.50 , resulting in gross proceeds of $3.0 million and net proceeds of $2.8 million after deducting underwriter fees and offering expenses. We entered into a securities purchase agreement, dated July 31, 2019 , for the sale of an aggregate of 3,960,560 shares of common stock at a price of $2.53 per share. Gross proceeds were approximately $10.0 million with net proceeds of $9.9 million after deducting fees and operating expenses. The initial closing, for 1,193,762 shares, took place on August 9, 2019 and gross proceeds were approximately $3.0 million , including 396,000 shares purchased by Park City Capital, a significant shareholder for $1.0 million . The second closing with a single investor, which was subject to additional conditions, including the execution of a definitive multi-year commercial agreement with an affiliate of the investor, for 2,766,798 shares and gross proceeds of $7.0 million took place on September 30, 2019 . We have a Form S-3 universal shelf registration statement on file with the SEC. The universal shelf registration statement on Form S-3 permits us to sell, in one or more public offerings, shares of our common stock, shares of preferred stock or debt securities, or any combination of such securities and warrants to purchase securities, for proceeds in an aggregate amount of up to $50.0 million , subject to potential limitations on the amount of securities we may sell in any twelve-month period. As of February 11, 2020 , we have raised a total of $28.8 million of gross proceeds from the sale of 19,166,667 shares of our common stock, leaving approximately $21.2 million of securities available for issuance pursuant to the Form S-3. The Form S-3 will expire in November 2021 . Preferred Stock Pursuant to our amended and restated certificate of incorporation, we are authorized to issue 3,000,000 shares of preferred stock. The board of directors has the authority, without action by our stockholders, to designate and issue shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. To-date, no preferred shares have been issued. Stock Repurchase Program On November 26, 2018, we announced that our board of directors had authorized a program to repurchase up to $4.0 million of our common stock over a 12-month period, either in the open market or through privately negotiated transactions. During the year ended December 31, 2018, we repurchased and retired 80,100 shares of common stock, at an aggregate cost of approximately $152,000 , including commissions, or an average price of $1.88 per share. There were no shares repurchased during the year ended December 31, 2019 and the program has expired. Earnings Per Share The following table presents the number of shares excluded from the calculation of diluted net loss per share attributable to common stockholders as of December 31, 2019 and 2018: 2019 2018 Common stock warrants 2,134,362 3,385,100 Common stock options 1,340,252 1,255,280 Non-vested restricted stock unit awards 2,556,004 1,921,594 Total shares excluded from net loss per share attributable to common stockholders 6,030,618 6,561,974

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION 2014 Omnibus Incentive Plan In January 2014, our board of directors approved the 2014 Omnibus Incentive Plan and amended and restated the plan in March 2014. Our stockholders approved the Amended and Restated 2014 Omnibus Incentive Plan, or the 2014 Plan, in March 2014. Our 2014 Plan initially permitted the issuance of equity-based instruments covering up to a total of 1,400,000 shares of common stock. Our board of directors and stockholders approved an increase of 1,300,000 shares in June 2016, an additional increase of 3,250,000 shares in June 2017, and an additional increase of 4,000,000 shares in June 2019, bringing the total shares allowed under the plan to 9,950,000 . As of December 31, 2019, there were 3,173,421 shares available to issue under the 2014 Plan. Option Valuation We account for stock options in accordance with ASC Topic 718, Compensation-Stock Compensation . As of January 1, 2019, we adopted ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting , which aligns the accounting of share-based payment awards issued to employees and non-employees. We use the Black-Scholes option valuation model for estimating fair value at the date of grant. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The expected term used for options is the estimated period of time that options granted are expected to be outstanding. We have estimated the expected life of stock options using the “simplified” method, whereby, the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to our lack of sufficient historical data. Since our stock has not been publicly traded for a sufficiently long period of time, we are utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within our industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. Stock Options During the years ended December 31, 2019 and 2018, we granted incentive stock options for the purchase of 154,500 and 252,500 shares, respectively, of our common stock to our employees and non-employees. The options granted in 2018 have an exercise price range of $1.80 to $5.96 per share with a term of ten years. The options granted in 2019 have an exercise price range of $1.52 to $3.26 per share with a term of ten years . The options vest over various periods, generally quarterly over sixteen quarters. The options granted in 2019 had an aggregate grant date fair value of $271,000 and the options granted in 2018 had an aggregate grant date fair value of $779,000 utilizing the Black-Scholes option valuation model. We estimated the fair value of stock options awarded during the years ended December 31, 2019 and 2018 using the Black-Scholes option valuation model. The fair values of stock options granted for the years were estimated using the following assumptions: Option Grants Awarded During the Year Ended December 31, 2019 Option Grants Awarded During the Year Ended December 31, 2018 Stock Price $1.52 - $3.26 $1.80 - $5.96 Dividend Yield 0% 0% Expected Volatility 70.0% 70.0% Risk-free interest rate 1.47% - 2.62% 2.50% - 3.09% Expected Term 7 years 7 years Stock-based compensation expense related to stock options was $430,000 and $476,000 for the years ended December 31, 2019 and 2018, respectively. We estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from our estimates. We use historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent that actual forfeitures differ from our estimates, the difference is recorded as a cumulative adjustment in the period the estimates were revised. For the years ended December 31, 2019 and 2018, we applied a forfeiture rate of six percent, which is reflected in our stock-based compensation expense related to stock options. Stock Option Award Activity The following is a summary of our stock option activity during the year ended December 31, 2018 : Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Outstanding, January 1, 2018 1,082,490 $ 4.87 $ 3.00 8.38 Granted 252,500 4.54 3.09 9.16 Exercised (4,692 ) 2.10 1.75 — Canceled/Forfeited (75,018 ) 4.72 2.89 — Outstanding, December 31, 2018 1,255,280 $ 4.82 $ 3.03 7.75 Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Exercisable, January 1, 2018 704,303 $ 5.08 $ 3.17 8.15 Vested 161,404 4.69 2.89 7.56 Exercised (4,692 ) 2.10 1.75 — Canceled/Forfeited (17,996 ) 4.72 2.84 — Exercisable, December 31, 2018 843,019 $ 5.02 $ 3.13 7.23 The following is a summary of our stock option activity during the year ended December 31, 2019 : Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Outstanding, January 1, 2019 1,255,280 $ 4.82 $ 3.03 7.75 Granted 154,500 2.61 1.76 9.44 Exercised — — — — Canceled/Forfeited (69,528 ) 4.72 3.03 — Outstanding, December 31, 2019 1,340,252 $ 4.57 $ 2.88 6.95 Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Exercisable, January 1, 2019 843,019 $ 5.02 $ 3.13 7.23 Vested 178,732 3.98 2.52 7.05 Exercised — — — — Canceled/Forfeited (32,659 ) 4.55 2.81 — Exercisable, December 31, 2019 989,092 $ 4.85 $ 3.03 6.37 The following table presents information related to stock options outstanding and exercisable at December 31, 2019 : Options Outstanding Options Exercisable Exercise Price Outstanding Number of Options Weighted Average Remaining Life In Years Exercisable Number of Options $1.52 - $3.15 310,683 6.52 158,650 $3.25 - $4.92 596,203 7.49 444,371 $5.01 - $6.00 273,066 4.93 240,755 $6.18 – $7.20 70,000 5.22 60,008 $7.54 – $7.80 67,800 5.21 62,808 $8.06 - $12.98 22,500 5.05 22,500 1,340,252 6.37 989,092 As of December 31, 2019 , there was $779,000 of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted average vesting period of approximately 2.4 years . The aggregate intrinsic value of outstanding options and options vested as of December 31, 2019 were $98,000 and $68,000 , respectively, representing options whose exercise price was less than the closing fair market value of our common stock of $2.42 per share. The aggregate intrinsic value of outstanding options and options vested as of December 31, 2018 were zero as there were no options whose exercise price was less than the closing fair market value of our common stock of $1.33 per share. There were no excess tax benefits realized for tax deductions from stock options exercised during the years ended December 31, 2018 and 2019 as we have recorded a full valuation allowance against our deferred income taxes. Restricted Stock Units Activity We account for restricted stock units (RSUs) issued to employees at fair value, based on the market price of our stock on the date of grant, net of estimated forfeitures. The fair value of non-employee restricted stock units awarded are re-measured as the awards vest, and the resulting increase in fair value, if any, is recognized as expense in the period the related services are rendered. RSUs issued in connection with our employee incentive programs typically vest within 10 days of grant. All other RSUs, primarily issued as long term incentives, generally vest annually over three to four years. During the years ended December 31, 2019 and 2018 we recorded $5.4 million and $4.8 million , respectively, of stock-based compensation related to restricted stock units. A summary of restricted stock unit activity for the year ended December 31, 2018 is as follows: Number of Restricted Share Units Weighted-Average Grant-Date Fair Value Per Share Outstanding at January 1, 2018 1,476,858 $ 4.96 Granted 1,661,750 4.60 Vested (1,051,939 ) 4.68 Forfeited (165,075 ) 5.17 Outstanding at December 31, 2018 1,921,594 $ 4.78 A summary of restricted stock unit activity for the year ended December 31, 2019 is as follows: Number of Restricted Share Units Weighted-Average Grant-Date Fair Value Per Share Outstanding at January 1, 2019 1,921,594 $ 4.78 Granted 2,115,177 2.78 Vested (1,317,586 ) 3.92 Forfeited (163,181 ) 4.19 Outstanding at December 31, 2019 2,556,004 $ 3.38 As of December 31, 2019 , there was 5.5 million of unrecognized compensation expense related to unvested restricted stock unit agreements which is expected to be recognized over a weighted-average period of approximately 2.1 years . For restricted stock unit awards subject to graded vesting, we recognize compensation cost on a straight-line basis over the service period for the entire award. Market-based Awards In August 2016, we granted 250,000 market-based restricted stock units to an executive. The restricted stock units are subject to market-based vesting requirements, measured quarterly, based on the average of (a) the average high daily trading price of our common stock for each trading day during the last month of the applicable calendar quarter and (b) the average low daily trading price of our common stock for each trading day during the last month of the applicable calendar quarter, each as reported by The Nasdaq Stock Market, LLC. The restricted stock units are eligible to be earned on a quarterly basis based on a linear interpolation of the applicable share price, or in the case of a liquidation event, on the day of (or in connection with) such liquidation event based on the applicable transaction price. The share price on the date of issuance was $5.06 per share. In June 2019, the market-based award was modified to increase the number of restricted stock units to 500,000 and to decrease the applicable share price. Additionally, the performance period was extended to September 30, 2022 . The share price on the date of modification was $2.73 per share. Once earned, the restricted stock units vest 50% on the date such restricted stock units become earned and 50% on September 30, 2022 . We recognize compensation expense for restricted stock units with market conditions using a graded vesting model, based on the probability of the market condition being met, net of estimated pre-vesting forfeitures. To determine the fair value of the award, we used a Monte Carlo simulation, which simulates future stock prices for the Company and, hence, shares vested, pursuant to the award. A key input into the model is the expected volatility for our stock. This estimate considered the historical volatility of our stock as well as the stock price volatility of guideline public companies. The fair value was determined to be $74,000 at the original grant date, and was $147,000 as of the modification date. For the years ended December 31, 2019 and 2018, we recognized $37,000 and $24,000 of stock compensation expense in connection with this award, which is included in sales, marketing and administration expenses. The unamortized expense related to this award is $116,000 and is expected to be recognized over 2.8 years. In December 2019, we granted 200,000 market-based restricted stock units to an executive. The restricted stock units are subject to the same market-based vesting requirements discussed for the award granted in August 2016 and modified in June 2019. The share price on the date of issuance was $2.15 per share and the fair value was determined to be $26,000 using a Monte Carlo simulation. We recognized $2,000 of stock compensation expense in connection with this award, which is included in research and development expenses. The unamortized expense related to this award is $24,000 and is expected to be recognized over 2.75 years. Incentive Bonus Awards We provide eligible employees, including executives, the opportunity to earn bonus awards upon achievement of predetermined performance goals and objectives. The purpose is to reward attainment of company goals and/or individual performance objectives, with award opportunities expressed as a percentage of base salary. Bonuses can be measured and paid quarterly and/or annually, and are paid in cash, equity or a combination of cash and equity, in the discretion of our compensation committee. If paid in the form of equity, the expense is included in the above disclosures for stock options or restricted stock units as applicable. Total stock-based compensation recorded in the consolidated statements of comprehensive loss is allocated as follows: Year Ended Year Ended December 31, 2018 Research and development 2,823,000 2,556,000 Sales, marketing and administration 2,983,000 2,706,000 Total stock-based compensation $ 5,806,000 $ 5,262,000

LEASES LEASES

LEASES LEASES	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
LEASES	LEASES We lease facilities under two non-cancelable operating leases. The leases expire between January 2022 and August 2024 and include renewal provisions for two to five years , provisions which require us to pay taxes, insurance, maintenance costs or provisions for minimum rent increases. We also lease facilities and equipment under short-term agreements for a period of 12 months or less. All of the information presented below, with the exception of total lease costs, relates to our two non-cancelable operating leases. One lease requires us to maintain a cash security deposit of $50,000 and also a $150,000 letter of credit in favor of the lessor. The letter of credit was originally for $200,000 at lease inception and steps down $50,000 at each anniversary date if there have been no monetary defaults. The letter of credit is secured by a pledge in favor of the issuing bank of a $150,000 mutual fund account which is classified as restricted cash in our balance sheet. Lease renewal options are at our discretion. No renewal options have been recognized in our right-of-use assets and lease liabilities as of December 31, 2019. Our lease agreements do not require material variable minimum lease payments, residual value guarantees or restrictive covenants. The depreciable lives of operating lease assets and leasehold improvements are limited by the expected lease term. Our leases generally do not provide an implicit rate, and therefore we use our incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate we would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease. We used a weighted average incremental borrowing rate of 4.75% as of January 1, 2019 for operating leases that commenced prior to that date. The discount rates applied to each lease reflect our estimated incremental borrowing rate. This includes an assessment of our credit rating to determine the rate that we would have to pay to borrow, on a collateralized basis for a similar term, an amount equal to our lease payments in a similar economic environment. The Company's weighted average remaining lease term and weighted average discount rate for operating leases as of December 31, 2019 is shown below: Weighted average remaining lease term (years) 4.24 Weighted average discount rate (%) 4.75 The table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining years to the total operating lease liabilities recognized on the condensed consolidated balance sheets as of December 31, 2019: 2020 726,000 2021 748,000 2022 557,000 2023 555,000 2024 376,000 Total minimum lease payments 2,962,000 Less: imputed interest (291,000 ) Total operating lease liabilities $ 2,671,000 Operating lease costs were $1,066,000 for the year ended December 31, 2019, of which $803,000 and $263,000 are included in research and development expenses and sales, marketing and administration expenses, respectively. Prior to the adoption of ASC 842, we recorded rent expense for the year ended December 31, 2018 of $663,000 of which $158,000 and $505,000 are included in research and development expenses and sales, marketing and administration expenses, respectively. Cash paid for amounts included in the measurement of operating lease liabilities was $492,000 for the year ended December 31, 2019, and this amount is included in operating activities in the consolidated statement of cash flows. The future minimum obligations under operating leases in effect as of December 31, 2018 having a noncancelable term in excess of one year are as follows: December 31, 2018 2019 $ 658,000 2020 726,000 2021 748,000 2022 557,000 2023 555,000 2024 376,000 Future minimum obligations $ 3,620,000

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The provision for income taxes by jurisdiction consists of the following as of December 31, 2019 and 2018: 2019 2018 U.S. federal: Current $ — $ — Deferred — — Total U.S. federal — — U.S. state and local: Current 1,000 2,000 Deferred — — Total U.S. state and local 1,000 2,000 Foreign: Current — — Deferred — (1,000 ) Total foreign — (1,000 ) Provision for income taxes $ 1,000 $ 1,000 Income taxes differ from the amounts computed by applying the U.S. federal income tax rate to pretax income (loss) before income taxes as a result of the following: 2019 2018 Expected income tax benefit $ (6,284,000 ) $ (5,211,000 ) State income tax (benefit), net of federal benefit (2,476,000 ) (1,997,000 ) Valuation allowance 9,131,000 7,372,000 Permanent differences: Stock options 493,000 285,000 Research & development credit (715,000 ) (405,000 ) Adjustment to deferred taxes (157,000 ) (68,000 ) Foreign rate differential 1,000 2,000 Other 8,000 23,000 Provision for income taxes $ 1,000 $ 1,000 For each of the years ended December 31, 2019 and 2018 we recorded a net income tax provision of $1,000 . Deferred income tax reflects the tax effects of temporary differences that gave rise to significant portions of our deferred tax assets and liabilities. Deferred income tax consists of the following: As of December 31, 2019 As of December 31, 2018 U.S. federal and state deferred tax assets—long term: Accrued payroll 261,000 $ 102,000 Accrued expenses 77,000 45,000 Intangibles 390,000 418,000 Research & development credit 3,651,000 2,239,000 Net operating loss 27,568,000 20,140,000 Stock compensation 672,000 612,000 Lease liabilities 750,000 — New jobs credit 8,000 8,000 Total long-term assets 33,377,000 23,564,000 Total deferred tax assets 33,377,000 23,564,000 U.S. federal and state deferred tax liabilities—long term: Fixed assets — (16,000 ) Right of use assets (701,000 ) — Total deferred tax liabilities (701,000 ) (16,000 ) Net deferred tax assets - long term 32,676,000 23,548,000 Less: Valuation allowance (32,676,000 ) (23,548,000 ) Net deferred tax assets $ — $ — Foreign deferred tax assets—long term: Net operating loss 8,000 $ 9,000 Total foreign deferred tax assets 8,000 9,000 Foreign deferred tax liabilities—long term: Intangibles — (4,000 ) Total foreign deferred tax liabilities $ — (4,000 ) Net foreign deferred tax assets (liabilities) 8,000 5,000 Less: Valuation allowance (8,000 ) (5,000 ) Net deferred tax assets (liabilities) — $ — In December 2017, the Tax Cuts and Jobs Act (the “2017 Tax Act”) was enacted. The 2017 Tax Act represents major tax reform legislation that, among other provisions, reduced the U.S. corporate tax rate. The reduction in the tax rate reduced our federal and state net deferred tax assets by $6.1 million , primarily related to our net operating loss carryforwards. Due to the full valuation allowance recorded against our federal and state net deferred tax assets, there was no impact to our income tax expense for the year ended December 31, 2019 or 2018. We recorded a full valuation allowance against our U.S. federal and state net deferred tax assets at December 31, 2019 and December 31, 2018. In determining the need for a valuation allowance, we reviewed all available evidence pursuant to the requirements of FASB ASC Topic 740, Income Taxes . Based upon our assessment of all available evidence, we have concluded that it is more likely than not that the net deferred tax assets will not be realized. For the year ended December 31, 2019, the valuation allowance increased by $9.1 million . For the year ended December 31, 2018 , the valuation allowance increased by $7.4 million . As of December 31, 2019 , we had federal net operating loss carryforwards of approximately $98.2 million , state net operating loss carryforwards of approximately $99.6 million and foreign net operating loss carryforwards of $51,000 in Switzerland. In accordance with the 2017 Tax Act, the $51.4 million federal net operating loss carryforwards generated on or after January 1, 2018 will not expire and will be limited to 80% usage. The federal net operating loss carryforwards generated prior to January 1, 2018 will begin to expire in 2033, and the state net operating loss carryforwards will begin to expire in 2033. Our ability to utilize net operating loss carryforwards may be limited in the event that a change in ownership, as defined in Section 382 of the Internal Revenue Code, occurs in the future. In the event a change of ownership occurs, it will limit the annual usage of the carryforwards in future years. Management believes that certain changes in control have occurred which resulted in limitations on our net operating loss carryforwards; however, management has determined that these limitations will not impact the ultimate utilization of the net operating loss carryforwards. We recognize interest and penalties related to income tax matters in income taxes, and there were none during the years ended December 31, 2019 and 2018. ASC 740 guidance requires us to identify, evaluate and measure all uncertain tax positions taken or to be taken on tax returns and to record liabilities for the amount of these positions that may not be sustained, or may only partially be sustained, upon examination by the relevant taxing authorities. Although we believe that our estimates and judgments are reasonable, actual results may differ from these estimates. Some or all of these judgments are subject to review by the taxing authorities. We have no significant uncertain tax positions for the years ended December 31, 2019 and 2018. Our annual income taxes and the determination of the resulting deferred tax assets and liabilities involve a significant amount of judgment. Our judgments, assumptions and estimates relative to current income taxes take into account current tax laws, their interpretation of current tax laws and possible outcomes of future audits conducted by domestic tax authorities. We operate within federal and state taxing jurisdictions and are subject to audit in these jurisdictions. These audits can involve complex issues which may require an extended period of time to resolve. We are currently not being examined by any tax authorities. We are subject to taxation in the United States, California, Massachusetts and Switzerland. As of December 31, 2019 , our tax years remain open to examination by the taxing authorities for all years since our incorporation in 2013.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Purchase Commitments —We have non-cancelable purchasing commitments that we incur in the ordinary course of business. The purchase commitments covered by these agreements are for less than one year and aggregate to $824,000 as of December 31, 2019 . Legal Proceedings —We are not party to any legal proceedings. We may, from time to time, be party to litigation and subject to claims incident to the ordinary course of business. As our growth continues, we may become party to an increasing number of litigation matters and claims. The outcome of litigation and claims cannot be predicted with certainty, and the resolution of any future matters could materially affect our future financial position, results of operations or cash flows. Legal fees and other costs associated with such actions are expensed as incurred. We assess, in conjunction with our legal counsel, the need to record a liability for litigation and contingencies. Litigation accruals are recorded when and if it is determined that a loss related matter is both probable and reasonably estimable. Material loss contingencies that are reasonably possible of occurrence, if any, are subject to disclosure. We evaluate developments in legal proceedings and other matters on a quarterly basis. As of December 31, 2018 and 2019 , there was no litigation or contingency with at least a reasonable possibility of a material loss. No losses have been recorded during the years ended December 31, 2018 and 2019 , respectively, with respect to litigation or loss contingencies. Intellectual Property Indemnities —We indemnify certain customers and manufacturers against liability arising from third-party claims of intellectual property rights infringement related to our products. These indemnities may appear in license agreements, development agreements and manufacturing agreements, may not be limited in amount or duration and generally survive the expiration date of the contract. Given that the amount of any potential liabilities related to such indemnities cannot be determined until an infringement claim has been made, we are unable to determine the maximum amount of losses that we could incur related to such indemnifications. Director and Officer Indemnities and Contractual Guarantees —We have entered into indemnification agreements with our directors and executive officers, which require us to indemnify such individuals to the fullest extent permitted by Delaware law. Our indemnification obligations under such agreements are not limited in amount or duration. Certain costs incurred in connection with such indemnifications may be recovered under certain circumstances under various insurance policies. Given that the amount of any potential liabilities related to such indemnities cannot be determined until a lawsuit has been filed, we are unable to determine the maximum amount of losses that we could incur relating to such indemnities. We have also entered into severance and change in control agreements with certain of our executives. These agreements provide for the payment of specific compensation benefits to such executives upon the termination of their employment with us. Guarantees and Indemnities —In the normal course of business, we are occasionally required to undertake indemnification for which we may be required to make future payments under specific circumstances. We review our exposure under such obligations no less than annually, or more frequently as required. The amount of any potential liabilities related to such obligations cannot be accurately determined until a formal claim is filed. Historically, any such amounts that become payable have not had a material negative effect on our business, financial condition or results of operations. We maintain general and product liability insurance which may provide a source of recovery to us in the event of an indemnification claim.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS In August 2019 , we entered into a consulting agreement with a member of our board of directors. Under the agreement, the board member would provide technical advisory services for cash payments totaling $50,000 paid in twelve equal monthly installments as well as an award of restricted stock units equal in value to $100,000 as of the grant date. The restricted stock units vest in full on January 1, 2020 . No later than January 15, 2020 , the board member shall receive an additional grant of restricted stock units equal to $100,000 of value as of the grant date, provided that, as of the grant date of the second grant, the board member is still providing the technical advisory services to the company. The second grant will vest in full on December 31, 2020 . In the event the board member is still performing services to the company after 2020 , the Company will issue new grants equal to no less than $100,000 worth of restricted stock units in January of each additional year with such grants vesting at the end of each year so long as the services are still being provided. The agreement is cancelable at any time by either the Company or the board member. During the year ended December 31, 2019 , we recorded expenses of $21,000 in connection with the cash compensation portion of the consulting agreement, which is included in general and administrative expenses. Additionally, during the year ended December 31, 2019 , we recorded $68,000 related to the restricted stock unit award, which is included in selling, general and administrative expenses. As of December 31, 2019 , there were no amounts due to the board member under this consulting agreement.

EMPLOYEE BENEFIT PLAN

EMPLOYEE BENEFIT PLAN	12 Months Ended
	Dec. 31, 2019
Retirement Benefits [Abstract]
EMPLOYEE BENEFIT PLAN	EMPLOYEE BENEFIT PLAN We have a 401(k) Savings Retirement Plan that covers substantially all domestic employees who meet the plan’s eligibility requirements and provides for an employee elective contribution and employer matching contributions. We recorded matching contributions to the retirement plan of $497,000 and $372,000 for the years ended December 31, 2019 and 2018 , respectively.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS On February 6, 2020 , we entered into an underwriting agreement relating to an underwritten public offering of 16,666,667 shares of the Company’s common stock, $0.001 par value, at an offering price to the public of $1.50 per share. Pursuant to the underwriting agreement, the Company granted the underwriters a 30-day option to purchase up to an additional 2,500,000 shares of common stock on the same terms and conditions. The underwriters exercised their option with respect to all 2,500,000 additional shares on February 10, 2020 . We consummated the sale of an aggregate of 19,166,667 shares of our common stock, including the 2,500,000 shares subject to the underwriters’ over-allotment option, on February 11, 2020 , and received gross proceeds of approximately $28.8 million , or net proceeds of approximately $26.3 million after deducting the underwriting discount and estimated expenses payable by us.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates —The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. Significant estimates made in preparing these financial statements include (a) assumptions to calculate the fair values of financial instruments, warrants and equity instruments and other liabilities and the deferred tax asset valuation allowance and (b) the useful lives for depreciable and amortizable assets. Actual results could differ from those estimates. In the opinion of management, all adjustments, including normal recurring accruals considered necessary for a fair presentation, have been included.
Consolidation	Consolidation - The accompanying financial statements include the accounts of the Company and its wholly-owned subsidiary, GVR. All significant intercompany balances and transactions have been eliminated.
Cash and Cash Equivalents	Cash and Cash Equivalents —We consider all liquid instruments purchased with a maturity of three months or less to be cash equivalents.
Concentration of Credit Risk	Concentration of Credit Risk —We maintain bank accounts at one U.S. financial institution. The U.S. bank accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per account owner. GVR, our wholly owned Swiss-based subsidiary maintains checking accounts at one major national financial institution. Additionally, we maintain a checking account with a very minimal balance at one bank in South Korea, which is used to fund payroll and rent in South Korea. Management believes we are not exposed to significant credit risk due to the financial position of the depository institutions in which our deposits are held.
Restricted Cash	Restricted Cash —Restricted cash at December 31, 2018 and 2019 consists of a pledged mutual fund account which is held as collateral against a letter of credit issued in May 2018 in connection with the lease of our corporate headquarters. The terms of the letter of credit allow for a step-down of $50,000 annually upon performance of certain events, primarily no late or defaulted payments. See also Note 12- Commitments and Contingencies, for further details.
Investments	Investments —Securities held-to-maturity: Management determines the appropriate classification of debt securities at the time of purchase and reevaluates such designation as of each balance sheet date. Investment/debt securities are classified as held-to-maturity when we have the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest method. Such amortization is included in investment income. Interest on securities classified as held-to-maturity is included in interest and investment income. When the fair value of an investment instrument classified as held-to-maturity is less than its amortized cost, management assesses whether or not: (i) we have the intent to sell the instrument or (ii) it is more likely than not that we will be required to sell the instrument before its anticipated recovery. If either of these conditions is met, we must recognize an other-than-temporary impairment for the difference between the instrument’s amortized cost basis and its fair value, and include such amounts in other income (expense). For investment instruments that do not meet the above criteria and are not expected to be recovered at the amortized cost basis, the instrument is considered other-than-temporarily impaired. For these instruments, we separate the total impairment into the credit loss component and the amount of the loss related to other factors. In order to determine the amount of the credit loss, we calculate the recovery value by performing a discounted cash flow analysis based on the current cash flows and future cash flows management expects to recover. The discount rate is the effective interest rate implicit in the underlying instrument. The amount of the total other-than-temporary impairment related to credit loss is recognized in earnings and is included in other income (expense). The amount of the total other-than-temporary impairment related to other factors is recognized in other comprehensive income. For investment instruments that have other-than-temporary impairment recognized through earnings, if through subsequent evaluation there is a significant increase in the cash flow expected, the difference between the amortized cost basis and the cash flows expected to be collected is accreted as interest income.
Fair Value of Financial Instruments	Fair Value of Financial Instruments —We measure certain financial assets and liabilities at fair value based on the exit price notion, or price that would be received for an asset or paid to transfer a liability, in an orderly transaction between the market participants at the measurement date. The carrying amounts of our financial instruments, including cash equivalents, restricted cash, accounts receivable, investments held-to-maturity, accounts payable, and accrued liabilities, approximate fair value due to their short maturities.
Accounts Receivable	Accounts Receivable —Trade accounts receivable are stated net of allowances for doubtful accounts. Management estimates the allowance for doubtful accounts based on review and analysis of specific customer balances that may not be collectible, customer payment history and any other customer-specific information that may impact collectability of the receivable. Accounts are considered for write-off when they become past due and when it is determined that the probability of collection is remote.
Property and Equipment	Property and Equipment —Property and equipment consists of leasehold improvements associated with our corporate offices, software purchased during the normal course of business, equipment and office furniture and fixtures, all of which are recorded at cost. Depreciation and amortization is recorded using the straight-line method over the respective useful lives of the assets ranging from three to five years . Leasehold improvements are amortized over the shorter of lease term or useful life. Long-lived assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable.
Intangible Assets, net	Intangible Assets, net —Intangible assets are recorded at cost and amortized over the useful life. In the case of business combinations, intangible assets are recorded at fair value. At December 31, 2018 and December 31, 2019 , intangible assets, net, includes patents and a domain name and other intangible assets purchased as part of our acquisition of GVR, including customer relationships, technology and a trademark. Intangible assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. In certain cases, patents may expire or be abandoned as we no longer plan to pursue them. In such cases we write off the capitalized patent costs as patent abandonment costs which are included in research and development expenses.
Goodwill	Goodwill— Goodwill represents the difference between the price paid to acquire GVR and the fair value of the assets acquired, net of assumed liabilities. We review goodwill for impairment annually and whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable.
Revenue Recognition	Revenue Recognition —Revenue is recognized upon the transfer of control of promised goods or services to the customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue consists primarily of upfront non-refundable fees received in connection with filter design projects with customers and royalties. Our performance obligation is to design a licensable filter in accordance with customer specifications. The license of the completed design is considered part of this performance obligation as the design and licensing of the filter are highly interdependent. We recognize revenue over the course of the design development phase as our customers are able to benefit from our design services as they are provided, primarily by marketing the in-process design to their customers. We recognize revenue from our design services based on efforts expended to date. At the end of each reporting period, we reassess our measure of progress and adjust revenue when appropriate. We record the expenses related to these projects in the periods incurred and they are generally included in research and development expense. In most cases, upfront non-refundable payments related to design development are recognized over a period of 12 months to 18 months . Contracts generally include upfront non-refundable fees, intended to support our initial engineering product development efforts, and may include milestone payments based upon the successful completion of certain deliverables. Milestone payments represent variable consideration, and we use the "most likely amount" approach to determine the amount we ultimately expect to receive. At contract inception, we assess the likelihood of achieving milestones to estimate the total consideration we believe we will receive for our services. Upon completion of design services, our customers retain a license over the completed design. The license will typically last for a minimum of two years, and in many cases for the life of the design. Royalties are sales-based, and we recognize royalty revenue upon shipment, by our customer, of products that include our licensed design. Payment is generally due within 30 days. We apply the practical expedients available in ASC 606 to not disclose information about 1) remaining performance obligations that have original expected durations of one year or less and 2) variable consideration that is a sales-based or usage-based royalty.
Research and Development	Research and Development —Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with ASC Topic 730-10, Research and Development .
Operating Leases	Operating Leases —We lease office space and research facilities under operating leases. Certain lease agreements contain free or escalating rent payment provisions. As of January 1, 2019, we have adopted ASU No. 2016-02, Leases (Topic 842) as well as other clarifying and practical updates issued under Leases (Topic 842) applicable to us. We determine if an arrangement is a lease at lease inception. Operating leases are included in right-of-use (“ROU”) lease assets, other current liabilities (current portion of lease obligations), and long term lease obligations on our balance sheets. ROU lease assets represent our right to use an underlying asset for the lease term and lease obligations represent our obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use an incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset also includes any lease payments made and excludes lease incentives. We evaluate renewal options at lease inception and on an ongoing basis, and include renewal options which we are reasonably certain to exercise in our expected lease term when classifying leases and measuring lease liabilities. We allocate the consideration between lease and nonlease components and exclude nonlease components from our recognized lease assets and liabilities. See also Recent Accounting Pronouncements and Note 10 - Leases. Minimum lease payments, including scheduled rent increases, are recognized as lease expenses on a straight-line basis over the applicable lease term. We recognize lease expenses within research and development and sales, marketing and administration expenses on a straight-line basis over the lease term. We are not party to any leases for which we are the lessor.
Stock-Based Compensation	Stock-Based Compensation —We account for employee stock options in accordance with ASC Topic 718, Compensation-Stock Compensation . We use the Black-Scholes option valuation model for estimating fair value at the date of grant. We account for restricted stock units issued at fair value, based on the market price of our stock on the date of grant, net of estimated forfeitures. Compensation expense is recognized for the portion of the award that is ultimately expected to vest over the period during which the recipient renders the required services to the Company generally using the straight-line single option method. In the case of award modifications, we account for the modification in accordance with ASU No.2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting , whereby we recognize the effect of the modification in the period the award is modified. As of January 1, 2019, we adopted ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting , which aligns the accounting of share-based payment awards issued to employees and non-employees. The adoption did not materially impact our condensed consolidated financial statements. Stock-based compensation expense is included in research and development expenses and general and administrative expenses.
Earnings Per Share, or EPS	Earnings Per Share, or EPS —EPS is computed in accordance with ASC Topic 260, Earnings per Share , and is calculated using the weighted average number of common shares outstanding during each period. Diluted EPS assumes the conversion, exercise or issuance of all potential common stock equivalents unless the effect is to reduce a loss or increase the income per share. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options (using the treasury stock method), the exercise of warrants (using the if-converted method) and the vesting of restricted stock unit awards.
Income Taxes	Income Taxes —We account for income taxes in accordance with ASC Topic 740, Income Taxes , or ASC 740, which requires the recognition of deferred tax assets and liabilities for the future consequences of events that have been recognized in our consolidated financial statements or tax returns. The measurement of the deferred items is based on enacted tax laws. In the event the future consequences of differences between financial reporting bases and the tax bases of our assets and liabilities result in a deferred tax asset, ASC 740 requires an evaluation of the probability of being able to realize the future benefits indicated by such asset. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion or the entire deferred tax asset will not be realized. As part of the process of preparing our consolidated financial statements, we are required to estimate our income tax expense in each of the jurisdictions in which we operate. We also assess temporary differences resulting from differing treatment of items for tax and accounting differences. We record a valuation allowance to reduce the deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. For the period when we were organized as a limited liability company, we were treated as a partnership for federal and state income tax purposes under the entity classification domestic default rules. As of December 31, 2019 and December 31, 2018, no liability for unrecognized tax benefits was required to be reported. We recognize interest and penalties related to income tax matters in income taxes, and there were none for the years ended December 31, 2019 and December 31, 2018, respectively. We have filed, or are in the process of filing, tax returns that are subject to audit by the respective tax authorities. Although the ultimate outcome is unknown, we believe that any adjustments that may result from tax return audits are not likely to have a material, adverse effect on our consolidated results of operations, financial position or cash flows.
Foreign Currency Translation	Foreign Currency Translation —The Swiss Franc has been determined to be the functional currency for the net assets of our Swiss-based subsidiary. We translate the assets and liabilities to U.S. dollars at each reporting period using exchange rates in effect at the balance sheet date and record the effects of the foreign currency translation in accumulated other comprehensive loss in shareholders' equity. We translate the income and expenses to U.S. dollars at each reporting period using the average exchange rate in effect for the period and record the effects of the foreign currency translation as other comprehensive income (loss) in the condensed consolidated statements of comprehensive loss. Gains and losses resulting from foreign currency transactions are included in net loss in the condensed consolidated statements of comprehensive loss.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Leases— In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , which, among other things required the recognition of lease assets and lease liabilities on the balance sheet for substantially all leases, including operating leases. Expanded disclosures with additional qualitative and quantitative information are also required. ASU 2016-02 and its amendments are effective for interim and annual reporting periods beginning after December 15, 2018 and early adoption was permitted. The standard allows for two methods of transition, one of which allows for the guidance to be applied to all leases existing at the adoption date with a cumulative effect adjustment to the opening balance sheet of retained earnings. Under this transition approach, comparative periods presented in the financial statements remain under legacy lease guidance. We adopted the standard, as well as certain practical expedients included therein, utilizing the optional transition method as of January 1, 2019. Therefore, we have not restated comparative periods in our 2019 financial statements and prior periods are not included in our leased properties footnote. The adoption did not have any cumulative adjustment impact on retained earnings. We elected the package of practical expedients permitted under the transition guidance, which allowed us to carry forward our historical assessments of: (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs. In addition, we did not elect the hindsight practical expedient to determine the reasonably certain lease term for existing leases. We also elected a policy of not recording leases on our condensed consolidated balance sheets when the leases have a term of 12 months or less and we are not reasonably certain to elect an option to purchase the leased asset. The adoption of the standard on January 1, 2019 caused us to recognize approximately $3.0 million in each, right-of-use assets and lease liabilities, in our condensed consolidated financial statements. The right-of-use asset balance reflects the impact of other liability amounts, specifically deferred rent, that has been effectively reclassified. The standard did not materially impact consolidated net income or liquidity.

REVENUE RECOGNITION (Tables)

REVENUE RECOGNITION (Tables)	12 Months Ended
	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Contract with Customer, Asset and Liability	Summary of changes in contract assets and liabilities for the years ended December 31, 2019 and 2018: 2019 2018 Contract assets Contract assets, beginning $ 36,000 $ 67,000 Contract assets at beginning of year transferred to accounts receivable (36,000 ) (43,000 ) Reversal of contract assets due to changes in transaction price (8,000 ) (24,000 ) Contract assets recorded on contracts during the period 8,000 36,000 Contract assets, ending $ — $ 36,000 Contract liabilities Contract liabilities, beginning $ 271,000 $ 146,000 Recognition of revenue included in beginning of year contract liabilities (209,000 ) (138,000 ) Contract liabilities, net of revenue recognized on contracts during the period 1,669,000 263,000 Contract liabilities, ending $ 1,731,000 $ 271,000
Disaggregation of Revenue	The following table presents our disaggregated revenue by geographic region: 2019 2018 Revenue by geographic region: United States $ 735,000 $ 447,000 Switzerland — 77,000 Total revenue $ 735,000 $ 524,000

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net, consists of the following as of December 31, 2019 and 2018: 2019 2018 Cost: Computers, peripheral and scientific equipment $ 1,654,000 $ 1,350,000 Software 2,131,000 1,749,000 Leasehold improvements 310,000 294,000 Office furniture and equipment 424,000 391,000 4,519,000 3,784,000 Less: Accumulated depreciation and amortization (2,634,000 ) (1,797,000 ) Property and equipment, net $ 1,885,000 $ 1,987,000

INTANGIBLE ASSETS, NET, AND G_2

INTANGIBLE ASSETS, NET, AND GOODWILL (Tables)	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Intangible assets, net, consists of the following as of December 31, 2019 and 2018: 2019 2018 Cost: Patents $ 1,801,000 $ 1,507,000 Domain name 22,000 22,000 Client Base (1) 144,000 142,000 Trademark (1) 18,000 17,000 Backlog (1) 13,000 13,000 Technology 77,000 77,000 2,075,000 1,778,000 Less: Accumulated amortization (499,000 ) (404,000 ) Intangible assets, net $ 1,576,000 $ 1,374,000 (1) Includes the impact of foreign currency translation. The total impact at December 31, 2018 was $1,000 and there was no impact at December 31, 2019 .
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The following table summarizes the estimated amortization expense relating to the intangible assets as of December 31, 2019 : Years ending December 31, 2020 $ 94,000 2021 85,000 2022 75,000 2023 72,000 2024 71,000 2025 and thereafter 554,000 Total amortization expense $ 951,000
Schedule of Goodwill	The following table summarizes goodwill arising from the acquisition of GVR Trade: Goodwill Balance at January 1, 2018 $ 824,000 Effect of currency translation (7,000 ) Balance at December 31, 2018 $ 817,000 Effect of currency translation 14,000 Balance at December 31, 2019 $ 831,000

WARRANTS (Tables)

WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2019
Warrants and Rights Note Disclosure [Abstract]
Schedule of Warrant Activity	A roll-forward of warrant activity from January 1, 2018 to December 31, 2018 is shown in the following table: Issued and Warrants Issued and Bridge Warrants 249,999 (249,999 ) (1) — Consulting Warrant 12,223 (5,556 ) (2) 6,667 Financing Warrant 62,530 — 62,530 Underwriting Warrant 310,500 — 310,500 IR Consulting Warrant 6,000 (6,000 ) (3) — Private Placement Warrants - 2016 891,063 (73,000 ) (4) 818,063 Underwriting Warrants - Public Offering 2016 122,175 — 122,175 Private Placement Warrants - September 2017 1,976,919 (10,600 ) (5) 1,966,319 Placement Agent Warrants - 2017 98,846 — 98,846 3,730,255 (345,155 ) 3,385,100 (1) During the year ended December 31, 2018, there were 249,999 warrants that were exchanged for 242,913 shares of common stock in an exchange transaction where the warrant holders exchanged the warrants for the same number of shares they would have been entitled to in a cashless exercise. (2) During the year ended December 31, 2018, there were 5,556 warrants that were exercised through a cashless exercise, which netted 5,542 shares being issued. (3) During the year ended December 31, 2018, 6,000 warrants expired. (4) During the year ended December 31, 2018, there were 73,000 warrants exercised for cash. (5) During the year ended December 31, 2018, there were 10,600 warrants exercised for cash. A roll-forward of warrant activity from January 1, 2019 to December 31, 2019 is shown in the following table: Exercise Price Expiration Date Issued and Warrants Issued and Consulting Warrant $0.01 6/17/2020 6,667 — 6,667 Financing Warrant $3.35 6/17/2020 62,530 — 62,530 Underwriting Warrant $7.50 5/28/2019 310,500 (310,500 ) (1) — Private Placement Warrants - 2016 $2.86 4/25/2019 818,063 (818,063 ) (2) — Underwriting Warrants - Public Offering 2016 $4.25 9/9/2019 122,175 (122,175 ) (3) — Private Placement Warrants - September 2017 $4.85 9/28/2020 1,966,319 — 1,966,319 Placement Agent Warrants - 2017 $4.85 9/28/2020 98,846 — 98,846 3,385,100 (1,250,738 ) 2,134,362 (1) During the year ended December 31, 2019, 310,500 warrants expired. (2) During the year ended December 31, 2019, there were 485,000 warrants exercised for cash, including 335,000 warrants exercised by our significant shareholder, Park City Capital. Additionally, there were 44,928 warrants that were exercised through a cashless exercise which netted 1,809 shares being issued and 288,135 warrants that expired. (3) During the year ended December 31, 2019, 122,175 warrants expired.

STOCKHOLDERS_ EQUITY AND EARN_2

STOCKHOLDERS’ EQUITY AND EARNINGS PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2019
Stockholders' Equity Note [Abstract]
Schedule of Repurchase Agreements	The following table presents the number of shares excluded from the calculation of diluted net loss per share attributable to common stockholders as of December 31, 2019 and 2018: 2019 2018 Common stock warrants 2,134,362 3,385,100 Common stock options 1,340,252 1,255,280 Non-vested restricted stock unit awards 2,556,004 1,921,594 Total shares excluded from net loss per share attributable to common stockholders 6,030,618 6,561,974

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Schedule of Fair Values of Stock Options Granted, Estimated Using Black-Scholes Option Valuation Model Assumptions	The fair values of stock options granted for the years were estimated using the following assumptions: Option Grants Awarded During the Year Ended December 31, 2019 Option Grants Awarded During the Year Ended December 31, 2018 Stock Price $1.52 - $3.26 $1.80 - $5.96 Dividend Yield 0% 0% Expected Volatility 70.0% 70.0% Risk-free interest rate 1.47% - 2.62% 2.50% - 3.09% Expected Term 7 years 7 years
Summary of Stock Option Activity	The following is a summary of our stock option activity during the year ended December 31, 2018 : Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Outstanding, January 1, 2018 1,082,490 $ 4.87 $ 3.00 8.38 Granted 252,500 4.54 3.09 9.16 Exercised (4,692 ) 2.10 1.75 — Canceled/Forfeited (75,018 ) 4.72 2.89 — Outstanding, December 31, 2018 1,255,280 $ 4.82 $ 3.03 7.75 Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Exercisable, January 1, 2018 704,303 $ 5.08 $ 3.17 8.15 Vested 161,404 4.69 2.89 7.56 Exercised (4,692 ) 2.10 1.75 — Canceled/Forfeited (17,996 ) 4.72 2.84 — Exercisable, December 31, 2018 843,019 $ 5.02 $ 3.13 7.23 The following is a summary of our stock option activity during the year ended December 31, 2019 : Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Outstanding, January 1, 2019 1,255,280 $ 4.82 $ 3.03 7.75 Granted 154,500 2.61 1.76 9.44 Exercised — — — — Canceled/Forfeited (69,528 ) 4.72 3.03 — Outstanding, December 31, 2019 1,340,252 $ 4.57 $ 2.88 6.95 Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Exercisable, January 1, 2019 843,019 $ 5.02 $ 3.13 7.23 Vested 178,732 3.98 2.52 7.05 Exercised — — — — Canceled/Forfeited (32,659 ) 4.55 2.81 — Exercisable, December 31, 2019 989,092 $ 4.85 $ 3.03 6.37
Schedule of Information Related To Stock Options Outstanding and Exercisable	The following table presents information related to stock options outstanding and exercisable at December 31, 2019 : Options Outstanding Options Exercisable Exercise Price Outstanding Number of Options Weighted Average Remaining Life In Years Exercisable Number of Options $1.52 - $3.15 310,683 6.52 158,650 $3.25 - $4.92 596,203 7.49 444,371 $5.01 - $6.00 273,066 4.93 240,755 $6.18 – $7.20 70,000 5.22 60,008 $7.54 – $7.80 67,800 5.21 62,808 $8.06 - $12.98 22,500 5.05 22,500 1,340,252 6.37 989,092
Schedule of Share-based Compensation, Restricted Stock Units Award Activity	A summary of restricted stock unit activity for the year ended December 31, 2018 is as follows: Number of Restricted Share Units Weighted-Average Grant-Date Fair Value Per Share Outstanding at January 1, 2018 1,476,858 $ 4.96 Granted 1,661,750 4.60 Vested (1,051,939 ) 4.68 Forfeited (165,075 ) 5.17 Outstanding at December 31, 2018 1,921,594 $ 4.78 A summary of restricted stock unit activity for the year ended December 31, 2019 is as follows: Number of Restricted Share Units Weighted-Average Grant-Date Fair Value Per Share Outstanding at January 1, 2019 1,921,594 $ 4.78 Granted 2,115,177 2.78 Vested (1,317,586 ) 3.92 Forfeited (163,181 ) 4.19 Outstanding at December 31, 2019 2,556,004 $ 3.38
Schedule of Stock-Based Compensation	Total stock-based compensation recorded in the consolidated statements of comprehensive loss is allocated as follows: Year Ended Year Ended December 31, 2018 Research and development 2,823,000 2,556,000 Sales, marketing and administration 2,983,000 2,706,000 Total stock-based compensation $ 5,806,000 $ 5,262,000

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Lessee, Operating Lease, Lease Terms	The Company's weighted average remaining lease term and weighted average discount rate for operating leases as of December 31, 2019 is shown below: Weighted average remaining lease term (years) 4.24 Weighted average discount rate (%) 4.75
Lessee, Operating Lease, Liability, Maturity	The future minimum obligations under operating leases in effect as of December 31, 2018 having a noncancelable term in excess of one year are as follows: December 31, 2018 2019 $ 658,000 2020 726,000 2021 748,000 2022 557,000 2023 555,000 2024 376,000 Future minimum obligations $ 3,620,000 The table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining years to the total operating lease liabilities recognized on the condensed consolidated balance sheets as of December 31, 2019: 2020 726,000 2021 748,000 2022 557,000 2023 555,000 2024 376,000 Total minimum lease payments 2,962,000 Less: imputed interest (291,000 ) Total operating lease liabilities $ 2,671,000

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Income Taxes By Jurisdiction	The provision for income taxes by jurisdiction consists of the following as of December 31, 2019 and 2018: 2019 2018 U.S. federal: Current $ — $ — Deferred — — Total U.S. federal — — U.S. state and local: Current 1,000 2,000 Deferred — — Total U.S. state and local 1,000 2,000 Foreign: Current — — Deferred — (1,000 ) Total foreign — (1,000 ) Provision for income taxes $ 1,000 $ 1,000
Schedule of Income Taxes Differ From The Amounts Computed By Applying The U.S. Federal Income tax rate to pretax income (loss) before income Taxes	Income taxes differ from the amounts computed by applying the U.S. federal income tax rate to pretax income (loss) before income taxes as a result of the following: 2019 2018 Expected income tax benefit $ (6,284,000 ) $ (5,211,000 ) State income tax (benefit), net of federal benefit (2,476,000 ) (1,997,000 ) Valuation allowance 9,131,000 7,372,000 Permanent differences: Stock options 493,000 285,000 Research & development credit (715,000 ) (405,000 ) Adjustment to deferred taxes (157,000 ) (68,000 ) Foreign rate differential 1,000 2,000 Other 8,000 23,000 Provision for income taxes $ 1,000 $ 1,000
Schedule of Components of Deferred Income Tax	Deferred income tax consists of the following: As of December 31, 2019 As of December 31, 2018 U.S. federal and state deferred tax assets—long term: Accrued payroll 261,000 $ 102,000 Accrued expenses 77,000 45,000 Intangibles 390,000 418,000 Research & development credit 3,651,000 2,239,000 Net operating loss 27,568,000 20,140,000 Stock compensation 672,000 612,000 Lease liabilities 750,000 — New jobs credit 8,000 8,000 Total long-term assets 33,377,000 23,564,000 Total deferred tax assets 33,377,000 23,564,000 U.S. federal and state deferred tax liabilities—long term: Fixed assets — (16,000 ) Right of use assets (701,000 ) — Total deferred tax liabilities (701,000 ) (16,000 ) Net deferred tax assets - long term 32,676,000 23,548,000 Less: Valuation allowance (32,676,000 ) (23,548,000 ) Net deferred tax assets $ — $ — Foreign deferred tax assets—long term: Net operating loss 8,000 $ 9,000 Total foreign deferred tax assets 8,000 9,000 Foreign deferred tax liabilities—long term: Intangibles — (4,000 ) Total foreign deferred tax liabilities $ — (4,000 ) Net foreign deferred tax assets (liabilities) 8,000 5,000 Less: Valuation allowance (8,000 ) (5,000 ) Net deferred tax assets (liabilities) — $ —

ORGANIZATION AND DESCRIPTION _2

ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) $ in Thousands	Feb. 11, 2020USD ($)	Feb. 29, 2020USD ($)	Dec. 31, 2019USD ($)Patent	Dec. 31, 2018USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit			$ 122,492	$ 92,564
Net loss			(29,928)	(24,816)
Cash used in operating activities			21,900
Existing cash balances and investments			$ 10,700
Number of developed intellectual property patents | Patent			200
Number of Developed Technology Patents | Patent			40
Subsequent Event [Line Items]
Net proceeds from the sale of common stock from underwritten public offering			$ 0	$ 21,190
Subsequent Event
Subsequent Event [Line Items]
Net proceeds from the sale of common stock from underwritten public offering	$ 26,300	$ 26,300

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	12 Months Ended
	Dec. 31, 2019USD ($)financial_institution	Dec. 31, 2018USD ($)	Jan. 01, 2019USD ($)
Accounting Policies [Abstract]
Number of financial institutions | financial_institution	1
Restricted cash balance	$ 50,000	$ 50,000
Income Taxes
Accounts receivable, allowance for credit loss	0	0
Unrecognized tax benefits	0	0
Income tax penalties and interest expense	0	$ 0
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease liability	2,671,000
Operating lease right-of-use assets	$ 2,496,000
Minimum
Property, Plant and Equipment [Line Items]
Useful lives	3 years
Upfront non-refundable design development payments, amortization period	12 months
Maximum
Property, Plant and Equipment [Line Items]
Useful lives	5 years
Upfront non-refundable design development payments, amortization period	18 months
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease liability			$ 3,000,000
Operating lease right-of-use assets			$ 3,000,000

REVENUE RECOGNITION (Schedule o

REVENUE RECOGNITION (Schedule of Changes in Contract Asset and Liability Balances) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Contract assets
Contract assets, beginning	$ 36	$ 67
Contract assets at beginning of year transferred to accounts receivable	(36)	(43)
Reversal of contract assets due to changes in transaction price	(8)	(24)
Contract assets recorded on contracts during the period	8	36
Contract assets, ending	0	36
Contract liabilities
Contract liabilities, beginning	271	146
Recognition of revenue included in beginning of year contract liabilities	(209)	(138)
Contract liabilities, net of revenue recognized on contracts during the period	1,669	263
Contract liabilities, ending	$ 1,731	$ 271

REVENUE RECOGNITION (Schedule_2

REVENUE RECOGNITION (Schedule of Revenue from Customer by Geographic Area and Source) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Disaggregation of Revenue [Line Items]
Revenues	$ 735	$ 524
United States
Disaggregation of Revenue [Line Items]
Revenues	735	447
Switzerland
Disaggregation of Revenue [Line Items]
Revenues	$ 0	$ 77

REVENUE RECOGNITION - Narrative

REVENUE RECOGNITION - Narrative (Details)	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Sep. 30, 2019USD ($)Licensing_Agreements
Disaggregation of Revenue [Line Items]
Minimum notice of cancellation	30 days
Contract exclusivity period	$ 735,000	$ 524,000
Proprietary Circuit Designs using XBAR Technology | Murata Manufacturing Co., Ltd.
Disaggregation of Revenue [Line Items]
Number of licensed radio frequencies or bands | Licensing_Agreements			4
Prepaid royalties			$ 9,000,000
Revenue from collaboration agreement	30 months
Accounts Receivable | Proprietary Circuit Designs using XBAR Technology | Murata Manufacturing Co., Ltd.
Disaggregation of Revenue [Line Items]
Contract exclusivity period	$ 2,000,000

INVESTMENTS HELD-TO-MATURITY (D

INVESTMENTS HELD-TO-MATURITY (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Schedule of Held-to-maturity Securities [Line Items]
Amortized cost		$ 16,900,000
Fair Value		16,900,000
Unrealized Gain (Loss)		0
Investments held-to-maturity	$ 0	16,863,000
Interest and investment income	$ 253,000	481,000
US Treasury Bills, Maturing April 2018 | Commercial Paper
Schedule of Held-to-maturity Securities [Line Items]
Investments held-to-maturity		25,000,000
Commercial Paper, Maturing In 2018 | Commercial Paper
Schedule of Held-to-maturity Securities [Line Items]
Investments held-to-maturity		$ 14,600,000

PROPERTY AND EQUIPMENT, NET (De

PROPERTY AND EQUIPMENT, NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property and equipment, gross	$ 4,519	$ 3,784
Less: Accumulated depreciation and amortization	(2,634)	(1,797)
Property and equipment, net	1,885	1,987
Depreciation	870	704
Property disposed of	31	773
Computers, peripheral and scientific equipment
Property and equipment, gross	1,654	1,350
Software
Property and equipment, gross	2,131	1,749
Leasehold improvements
Property and equipment, gross	310	294
Office furniture and equipment
Property and equipment, gross	$ 424	$ 391

INTANGIBLE ASSETS, NET, AND G_3

INTANGIBLE ASSETS, NET, AND GOODWILL (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Write-off of abandoned patents	$ 145	$ 96
Amortization of intangible assets	$ 115	$ 136
Patents | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life	17 years
Patents | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life	20 years
STI | Patents | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life	1 year
STI | Patents | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life	11 years
STI | Domain name
Finite-Lived Intangible Assets [Line Items]
Useful life	10 years
GVR Trade S.A. | Patents | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life	3 years
GVR Trade S.A. | Patents | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life	5 years

INTANGIBLE ASSETS, NET, AND G_4

INTANGIBLE ASSETS, NET, AND GOODWILL (Intangible Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2019
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	$ 1,778	$ 2,075
Less: Accumulated amortization	(404)	(499)
Total amortization expense	1,374	1,576
Impact of foreign currency translation	1
Patents
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	1,507	1,801
Domain name
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	22	22
Client Base
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	142	144
Trademark
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	17	18
Backlog
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	13	13
Technology
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	$ 77	$ 77

INTANGIBLE ASSETS, NET, AND G_5

INTANGIBLE ASSETS, NET, AND GOODWILL (Schedule of Future Amortization Expense) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Total amortization expense	$ 1,576	$ 1,374
Intangible Assets, Excluding Pending Patents
Finite-Lived Intangible Assets [Line Items]
2020	94
2021	85
2022	75
2023	72
2024	71
2025 and thereafter	554
Total amortization expense	$ 951

INTANGIBLE ASSETS, NET, AND G_6

INTANGIBLE ASSETS, NET, AND GOODWILL (Goodwill) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Goodwill [Roll Forward]
Balance at the beginning of the period	$ 817	$ 824
Effect of currency translation	14	(7)
Balance at the end of the period	$ 831	$ 817

WARRANTS (Narrative) (Details)

WARRANTS (Narrative) (Details) - USD ($)

Sep. 28, 2017

Apr. 25, 2016

Jun. 17, 2013

Dec. 31, 2017

Feb. 28, 2017

Sep. 30, 2016

Apr. 30, 2016

Oct. 31, 2017

Dec. 31, 2019

Dec. 31, 2018

Jan. 31, 2018

Oct. 02, 2017

Warrant liabilities

Warrants Exercised/ Expired

345,155

Common stock issued

$ 33,000

$ 27,000

Sale of common stock, net of offering costs

9,919,000

21,189,000

Proceeds from exercises of warrants

$ 1,387,000

$ 260,000

Common Stock

Warrant liabilities

Sales of common stock, net of offering costs (in shares)

3,960,560

6,571,428

Sale of common stock, net of offering costs

$ 4,000

$ 6,000

Placement Agents

Warrant liabilities

Implied unit price/stock price (in dollars per share)

$ 4.85

Placement Agents | Common Stock

Warrant liabilities

Period end after closing

2 years

Placement Agents | Private Placement, Offering One

Warrant liabilities

Sold in private placement (in shares)

87,279

Placement Agents | Private Placement, Offering Two

Warrant liabilities

Sold in private placement (in shares)

11,567

Financing Warrant

Warrant liabilities

Warrants Exercised/ Expired

0

Financing Warrant | MDB

Warrant liabilities

Warrants to purchase shares of common stock or units (in shares)

208,763

Exercise price (in dollars per share)

$ 3.35

Warrant term

7 years

Underwriting Warrant

Warrant liabilities

Warrants Exercised/ Expired

0

Sales of common stock, net of offering costs (in shares)

1,976,919

Underwriting Warrant | Common Stock

Warrant liabilities

Warrants to purchase shares of common stock or units (in shares)

2,715,000

Underwriting Warrant | Investors, Executives and Board Members

Warrant liabilities

Exercise price (in dollars per share)

$ 4.25

Underwriting Warrant | Investors, Executives and Board Members | Private Placement

Warrant liabilities

Sales of common stock, net of offering costs (in shares)

135,750

Underwriting Warrant | Placement Agents

Warrant liabilities

Sales of common stock, net of offering costs (in shares)

98,846

Underwriting Warrant | MDB

Warrant liabilities

Warrants to purchase shares of common stock or units (in shares)

310,500

Exercise price (in dollars per share)

$ 7.50

Warrant term

5 years

Warrants exercisable period from underwriting agreement

180 days

Private Placement Warrants

Warrant liabilities

Sale of common stock, net of offering costs

$ 2,400,000

Non-cash warrant inducement expense

239,000

Proceeds from exercises of warrants

$ 2,200,000

Private Placement Warrants | Private Placement

Warrant liabilities

Warrants to purchase shares of common stock or units (in shares)

1,996,880

836,780

Private Placement Warrants | Investors, Executives and Board Members

Warrant liabilities

Exercise price (in dollars per share)

$ 2.86

$ 2.86

Period start after closing

6 months

Period end after closing

36 months

Private Placement Warrants | Investors, Executives and Board Members | Private Placement

Warrant liabilities

Sales of common stock, net of offering costs (in shares)

1,996,880

Private Placement Warrants | Placement Agents

Warrant liabilities

Sales of common stock, net of offering costs (in shares)

99,844

836,780

Implied unit price/stock price (in dollars per share)

$ 2.86

Private Placement Warrants, September 2017

Warrant liabilities

Warrants Exercised/ Expired

10,600

Private Placement Warrants, September 2017 | Private Placement

Warrant liabilities

Warrants to purchase shares of common stock or units (in shares)

1,745,581

1,976,919

231,338

Period start after closing

6 months

Private Placement Warrants, September 2017 | Investors, Executives and Board Members | Capital Units

Warrant liabilities

Exercise price (in dollars per share)

$ 4.85

Private Placement Warrants, September 2017 | Investors, Executives and Board Members | Private Placement | Capital Units

Warrant liabilities

Sales of common stock, net of offering costs (in shares)

1,976,919

Bridge Warrants

Warrant liabilities

Warrants Exercised/ Expired

249,999

Bridge Warrants | Founders

Warrant liabilities

Warrants to purchase shares of common stock or units (in shares)

249,999

Exercise price (in dollars per share)

$ 0

$ 0.20

Warrants and rights outstanding, value

$ 1,600,000

Common stock issued

$ 1,600,000

Bridge Warrants | Sales, Marketing and Administration | Founders

Warrant liabilities

Fair value adjustment of warrants

$ 2,000

Consulting Warrant

Warrant liabilities

Warrants Exercised/ Expired

5,556

Consulting Warrant | MDB

Warrant liabilities

Warrants to purchase shares of common stock or units (in shares)

222,222

Exercise price (in dollars per share)

$ 0.01

Warrant term

7 years

Options Exercised, Cashless | Financing Warrant

Warrant liabilities

Warrants Exercised/ Expired

5,556

Options Exercised, Cashless | Private Placement Warrants

Warrant liabilities

Warrants Exercised/ Expired

73,000

WARRANTS (Schedule of Warrant A

WARRANTS (Schedule of Warrant Activity) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	3,385,100	3,730,255
Warrant exercised/expired (in shares)		(345,155)
Balance at the end of the period (in shares)		3,385,100
Bridge Warrants
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	0	249,999
Warrant exercised/expired (in shares)		(249,999)
Balance at the end of the period (in shares)		0
Consulting Warrant
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	6,667	12,223
Warrant exercised/expired (in shares)		(5,556)
Balance at the end of the period (in shares)		6,667
Exercise of warrants, cashless (in shares)		242,913
Financing Warrants
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	62,530	62,530
Warrant exercised/expired (in shares)		0
Balance at the end of the period (in shares)		62,530
Exercise of warrants, cashless (in shares)		5,542
Financing Warrants | Cashless
Roll forward of warrant activity
Warrant exercised/expired (in shares)		(5,556)
Underwriting Warrant
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	310,500	310,500
Warrant exercised/expired (in shares)		0
Balance at the end of the period (in shares)		310,500
IR Consulting Warrants
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	0	6,000
Warrant exercised/expired (in shares)		(6,000)
Balance at the end of the period (in shares)		0
Private Placement Warrants | Cashless
Roll forward of warrant activity
Warrant exercised/expired (in shares)		(73,000)
Private Placement Warrants - 2016
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	818,063	891,063
Warrant exercised/expired (in shares)	(288,135)	(73,000)
Balance at the end of the period (in shares)		818,063
Exercise of warrants, cashless (in shares)	1,809
Exercises of warrants, cashless (in warrants)	485,000
Stock issued during period shares warrants exercised, cashless exercise	44,928
Private Placement Warrants - 2016 | Cash
Roll forward of warrant activity
Stock issued during period shares warrants exercised, cashless exercise	335,000
Underwriting Warrants - Public Offering 2016
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	122,175	122,175
Warrant exercised/expired (in shares)	(122,175)	0
Balance at the end of the period (in shares)		122,175
Private Placement Warrants - September 2017
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	1,966,319	1,976,919
Warrant exercised/expired (in shares)		(10,600)
Balance at the end of the period (in shares)		1,966,319
Placement Agent Warrants - 2017
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	98,846	98,846
Warrant exercised/expired (in shares)		0
Balance at the end of the period (in shares)		98,846
Warrant
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	3,385,100
Warrant exercised/expired (in shares)	(1,250,738)
Balance at the end of the period (in shares)	2,134,362	3,385,100
Warrant | Consulting Warrant
Warrant liabilities
Exercise price (in dollars per share)	$ 0.01
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	6,667
Warrant exercised/expired (in shares)	0
Balance at the end of the period (in shares)	6,667	6,667
Warrant | Financing Warrants
Warrant liabilities
Exercise price (in dollars per share)	$ 3.35
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	62,530
Warrant exercised/expired (in shares)	0
Balance at the end of the period (in shares)	62,530	62,530
Warrant | Underwriting Warrant
Warrant liabilities
Exercise price (in dollars per share)	$ 7.50
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	310,500
Warrant exercised/expired (in shares)	(310,500)
Balance at the end of the period (in shares)	0	310,500
Warrant | Private Placement Warrants - 2016
Warrant liabilities
Exercise price (in dollars per share)	$ 2.86
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	818,063
Warrant exercised/expired (in shares)	(818,063)
Balance at the end of the period (in shares)	0	818,063
Warrant | Underwriting Warrants - Public Offering 2016
Warrant liabilities
Exercise price (in dollars per share)	$ 4.25
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	122,175
Warrant exercised/expired (in shares)	(122,175)
Balance at the end of the period (in shares)	0	122,175
Warrant | Private Placement Warrants - September 2017
Warrant liabilities
Exercise price (in dollars per share)	$ 4.85
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	1,966,319
Warrant exercised/expired (in shares)	0
Balance at the end of the period (in shares)	1,966,319	1,966,319
Warrant | Placement Agent Warrants - 2017
Warrant liabilities
Exercise price (in dollars per share)	$ 4.85
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	98,846
Warrant exercised/expired (in shares)	0
Balance at the end of the period (in shares)	98,846	98,846

STOCKHOLDERS_ EQUITY AND EARN_3

STOCKHOLDERS’ EQUITY AND EARNINGS PER SHARE (Details) - USD ($)	Feb. 11, 2020	Aug. 09, 2019	Jul. 31, 2019	Apr. 06, 2018	Mar. 27, 2018	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Nov. 26, 2018
Class of Stock [Line Items]
Common stock, shares authorized (in shares)							100,000,000	100,000,000
Sales of common stock, net of offering costs (in shares)		396,000	3,960,560
Share price (in dollars per share)			$ 2.53
Net proceeds from the sale of common stock from private placement offerings			$ 10,000,000				$ 9,919,000	$ 0
Sale of common stock, net of offering costs		$ 3,000,000	$ 9,900,000
Shares, outstanding		1,193,762
Expense, tax benefit						$ 2,766,798
Gross proceeds from the second closing						$ 7,000,000
Preferred stock, shares authorized (in shares)							3,000,000	3,000,000
Stock Repurchase Program [Abstract]
Authorized repurchase amount									$ 4,000,000
Repurchase and retirement of common stock								$ (152,000)
Repurchase and retirement of common stock, average price per share (in dollars per share)							$ 1.88
Shares excluded from computation of earnings per share (in shares)							6,030,618	6,561,974
Subsequent Event
Class of Stock [Line Items]
Sale of common stock, net of offering costs	$ 28,800,000
Underwritten Public Offering
Class of Stock [Line Items]
Sales of common stock, net of offering costs (in shares)				857,142	5,714,286
Share price (in dollars per share)				$ 3.50	$ 3.50
Net proceeds from the sale of common stock from private placement offerings				$ 3,000,000	$ 20,000,000
Sale of common stock, net of offering costs				$ 2,800,000	$ 18,400,000
Shelf registration statement, public offerings, maximum aggregate proceeds							$ 50,000,000
Underwritten Public Offering | Subsequent Event
Class of Stock [Line Items]
Sales of common stock, net of offering costs (in shares)	19,166,667
Reserved for future issuance (in shares)	21,200,000
Common stock options
Stock Repurchase Program [Abstract]
Repurchase and retirement of common stock (in shares)							0	(80,100)
Park City Capital
Class of Stock [Line Items]
Sale of common stock, net of offering costs		$ 1,000,000
Restricted stock units
Stock Repurchase Program [Abstract]
Shares excluded from computation of earnings per share (in shares)							2,556,004	1,921,594
Warrant
Stock Repurchase Program [Abstract]
Shares excluded from computation of earnings per share (in shares)							2,134,362	3,385,100
Common stock options
Stock Repurchase Program [Abstract]
Shares excluded from computation of earnings per share (in shares)							1,340,252	1,255,280

STOCK-BASED COMPENSATION (Narra

STOCK-BASED COMPENSATION (Narrative) (Details)	Sep. 30, 2022USD ($)	Sep. 30, 2019	Aug. 08, 2016	Jun. 30, 2019shares	Jun. 30, 2017shares	Aug. 31, 2016$ / sharesshares	Jun. 30, 2016shares	Dec. 31, 2019USD ($)quarter$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2014shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares) | shares								154,500	252,500
Grant date fair value								$ 271,000	$ 779,000
Stock compensation expense								2,000
Excess tax benefit from share-based compensation								$ 0	$ 0
Vesting period								2 years 9 months
Compensation cost not yet recognized								$ 24,000
Non-Vested Restricted Stock Unit Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares) | shares								154,500	252,500
Number of quarter over which awards vest from grant date subsequent to initial vesting | quarter								16
Stock compensation expense								$ 430,000	$ 476,000
Unrecognized compensation expense related to unvested employee stock option								$ 779,000
Compensation cost not yet recognized, period for recognition								2 years 5 months 1 day
Options outstanding, aggregate intrinsic value								$ 98,000	$ 0
Options vested, aggregate intrinsic value								$ 68,000
Share price (in dollars per share) | $ / shares								$ 1.33
Non-Vested Restricted Stock Unit Awards | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share) | $ / shares								1.52	$ 1.80
Non-Vested Restricted Stock Unit Awards | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share) | $ / shares								$ 3.26	$ 5.96
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense								$ 5,400,000	$ 4,800,000
Unrecognized compensation expense related to unvested employee stock option								$ 5,500,000
Compensation cost not yet recognized, period for recognition								2 years 1 month 6 days
Granted (in shares) | shares								2,115,177	1,661,750
Restricted stock units | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period								3 years
Restricted stock units | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period								4 years
2014 Omnibus Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock approved for issuance | shares				9,950,000						1,400,000
Number of additional shares authorized (in shares) | shares				4,000,000	3,250,000		1,300,000
Reserved for future issuance (in shares) | shares								3,173,421
2014 Omnibus Incentive Plan | Non-Vested Restricted Stock Unit Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award								10 years
2014 Omnibus Incentive Plan | Non-Vested Restricted Stock Unit Awards | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, lower limit (in dollars per share) | $ / shares								$ 1.80
2014 Omnibus Incentive Plan | Non-Vested Restricted Stock Unit Awards | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, upper limit (in dollars per share) | $ / shares								5.96
Employees | Non-Vested Restricted Stock Unit Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, lower limit (in dollars per share) | $ / shares								1.52
Exercise price range, upper limit (in dollars per share) | $ / shares								$ 3.26
Forfeitures rate								6.00%	6.00%
Employees | Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period								10 days
Employees and Consultants | Non-Vested Restricted Stock Unit Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award								10 years
Executive Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share) | $ / shares								$ 2.15
Executive Employees | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share) | $ / shares						$ 5.06		$ 2.73
Award vesting rights, percentage			50.00%
Granted (in shares) | shares				500,000		250,000		200,000
Executive Employees | Performance Based Awards | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage		50.00%
Common Stock | Non-Vested Restricted Stock Unit Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share) | $ / shares								$ 2.42
Common Stock | Executive Employees | 2015 Performance Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of award								$ 26,000
Common Stock | Executive Employees | 2015 Performance Plan | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense								$ 37,000	$ 24,000
Vesting period								2 years 9 months
Fair value of award								$ 74,000
Compensation cost not yet recognized								$ 116,000
Forecast | Common Stock | Executive Employees | 2015 Performance Plan | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of award	$ 147,000

STOCK-BASED COMPENSATION (Estim

STOCK-BASED COMPENSATION (Estimated Fair Value of Stock Options) (Details) - Non-Vested Restricted Stock Unit Awards - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share)	$ 1.33
Dividend Yield	0.00%	0.00%
Expected Volatility	70.00%	70.00%
Expected Life	7 years	7 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share)	$ 1.52	$ 1.80
Risk-free interest rate	1.47%	2.50%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share)	$ 3.26	$ 5.96
Risk-free interest rate	2.62%	3.09%

STOCK-BASED COMPENSATION (Stock

STOCK-BASED COMPENSATION (Stock Option Award Activity) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Number of Options outstanding
Outstanding at the beginning of the year (in shares)	1,255,280	1,082,490
Granted (in shares)	154,500	252,500
Exercised (in shares)	0
Canceled/Forfeited (in shares)	(69,528)	(75,018)
Outstanding at the end of the reporting period (in shares)	1,340,252	1,255,280	1,082,490
Number of Options Exercisable
Exercisable at the beginning of the year (in shares)	843,019	704,303
Vested (in shares)	(178,732)	(161,404)
Canceled/Forfeited (in shares)	(32,659)	(17,996)
Exercisable at the end of the reporting period (in shares)	989,092	843,019	704,303
Weighted Average Exercise Price Outstanding
Outstanding at the beginning of period (in dollars per share)	$ 4.82	$ 4.87
Granted (in dollars per share)	2.61	4.54
Exercised (in dollars per share)	0
Forfeited (in dollars per share)	4.72	4.72
Outstanding at the end of the reporting period (in dollars per share)	4.57	4.82	$ 4.87
Weighted Average Exercise Price Exercisable
Exercisable at the beginning of the reporting period (in dollars per share)	5.02	5.08
Vested exercisable (in dollars per share)	3.98	4.69
Canceled/Forfeited (in dollars per share)	4.55	4.72
Exercisable at the end of the reporting period (in dollars per share)	4.85	5.02	5.08
Weighted Average Grant Date Fair Value Outstanding
Outstanding at the beginning of the reporting period (in dollars per share)	3.03	3
Options granted (in dollars per share)	1.76	3.09
Exercised (in dollars per share)	0
Forfeited (in dollars per share)	3.03	2.89
Outstanding at the end of the reporting period (in dollars per share)	2.88	3.03	3
Weighted Average Grant Date Fair Value Exercisable
Exercisable at the beginning of the reporting period (in dollars per share)	3.13	3.17
Vested options exercisable (in dollars per share)	2.52	2.89
Forfeited options exercisable (in dollars per share)	2.81	2.84
Exercisable at the end of the reporting period (in dollars per share)	$ 3.03	$ 3.13	$ 3.17
Weighted Average Remaining Life In Years Outstanding
Outstanding at the end of the reporting period (in years)		7 years 9 months	8 years 4 months 17 days
Granted, Weighted average remaining life (in years)		9 years 1 month 28 days
Weighted Average Remaining Life Exercisable
Exercisable at the end of the reporting period (in years)		7 years 2 months 23 days	8 years 1 month 24 days
Vested, Weighted average remaining live (in years)		7 years 6 months 22 days
Non-Vested Restricted Stock Unit Awards
Number of Options outstanding
Granted (in shares)	154,500	252,500
Exercised (in shares)		(4,692)
Outstanding at the end of the reporting period (in shares)	1,340,252
Number of Options Exercisable
Exercisable at the end of the reporting period (in shares)	989,092
Weighted Average Exercise Price Outstanding
Exercised (in dollars per share)		$ 2.10
Weighted Average Grant Date Fair Value Outstanding
Exercised (in dollars per share)		$ 1.75
Weighted Average Remaining Life In Years Outstanding
Outstanding at the end of the reporting period (in years)	6 years 11 months 12 days	7 years 9 months
Granted, Weighted average remaining life (in years)	9 years 5 months 9 days
Weighted Average Remaining Life Exercisable
Exercisable at the end of the reporting period (in years)	6 years 4 months 13 days	7 years 2 months 23 days
Vested, Weighted average remaining live (in years)	7 years 18 days

STOCK-BASED COMPENSATION (Sto_2

STOCK-BASED COMPENSATION (Stock Options Outstanding and Exercisable) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	1,340,252	1,255,280	1,082,490
Weighted Average Remaining Life In Years		7 years 2 months 23 days	8 years 1 month 24 days
Exercisable Number of Options	989,092	843,019	704,303
Non-Vested Restricted Stock Unit Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	1,340,252
Weighted Average Remaining Life In Years	6 years 4 months 13 days	7 years 2 months 23 days
Exercisable Number of Options	989,092
Non-Vested Restricted Stock Unit Awards | $1.52 - $3.15
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	310,683
Weighted Average Remaining Life In Years	6 years 6 months 7 days
Exercisable Number of Options	158,650
Non-Vested Restricted Stock Unit Awards | $3.25 - $4.92
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	596,203
Weighted Average Remaining Life In Years	7 years 5 months 27 days
Exercisable Number of Options	444,371
Non-Vested Restricted Stock Unit Awards | $5.01 - $6.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	273,066
Weighted Average Remaining Life In Years	4 years 11 months 5 days
Exercisable Number of Options	240,755
Non-Vested Restricted Stock Unit Awards | $6.18 – $7.20
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	70,000
Weighted Average Remaining Life In Years	5 years 2 months 19 days
Exercisable Number of Options	60,008
Non-Vested Restricted Stock Unit Awards | $7.54 – $7.80
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	67,800
Weighted Average Remaining Life In Years	5 years 2 months 16 days
Exercisable Number of Options	62,808
Non-Vested Restricted Stock Unit Awards | $8.06 - $12.98
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	22,500
Weighted Average Remaining Life In Years	5 years 18 days
Exercisable Number of Options	22,500
Non-Vested Restricted Stock Unit Awards | Minimum | $1.52 - $3.15
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollar per share)	$ 1.52
Non-Vested Restricted Stock Unit Awards | Minimum | $3.25 - $4.92
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollar per share)	3.25
Non-Vested Restricted Stock Unit Awards | Minimum | $5.01 - $6.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollar per share)	5.01
Non-Vested Restricted Stock Unit Awards | Minimum | $6.18 – $7.20
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollar per share)	6.18
Non-Vested Restricted Stock Unit Awards | Minimum | $7.54 – $7.80
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollar per share)	7.54
Non-Vested Restricted Stock Unit Awards | Minimum | $8.06 - $12.98
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollar per share)	8.06
Non-Vested Restricted Stock Unit Awards | Maximum | $1.52 - $3.15
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollar per share)	3.15
Non-Vested Restricted Stock Unit Awards | Maximum | $3.25 - $4.92
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollar per share)	4.92
Non-Vested Restricted Stock Unit Awards | Maximum | $5.01 - $6.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollar per share)	6
Non-Vested Restricted Stock Unit Awards | Maximum | $6.18 – $7.20
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollar per share)	7.20
Non-Vested Restricted Stock Unit Awards | Maximum | $7.54 – $7.80
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollar per share)	7.80
Non-Vested Restricted Stock Unit Awards | Maximum | $8.06 - $12.98
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollar per share)	$ 12.98

STOCK-BASED COMPENSATION (Restr

STOCK-BASED COMPENSATION (Restricted Stock Activity) (Details) - Restricted stock units - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Restricted Share Units
Outstanding at beginning of year (in shares)	1,921,594	1,476,858
Granted (in shares)	2,115,177	1,661,750
Vested (in shares)	(1,317,586)	(1,051,939)
forfeited (in shares)	(163,181)	(165,075)
Outstanding at end of year (in shares)	2,556,004	1,921,594
Restricted Share Weighted Average Grant Date Fair Value
Outstanding at beginning of year (in dollars per share)	$ 4.78	$ 4.96
Granted (in dollars per share)	2.78	4.60
Vested (in dollars per share)	3.92	4.68
forfeited (in dollars per share)	4.19	5.17
Outstanding at end of year (in dollars per share)	$ 3.38	$ 4.78

STOCK-BASED COMPENSATION (Equit

STOCK-BASED COMPENSATION (Equity Based Compensation Schedule) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Allocation of stock-based compensation expense
Stock compensation expense	$ 5,806,000	$ 5,262,000
Research and development
Allocation of stock-based compensation expense
Stock compensation expense	2,823,000	2,556,000
Sales, marketing and administration
Allocation of stock-based compensation expense
Stock compensation expense	$ 2,983,000	$ 2,706,000

LEASES Narrative (Details)

LEASES Narrative (Details) $ in Thousands	Jan. 01, 2019	Dec. 31, 2019USD ($)Lease	Dec. 31, 2018USD ($)
Lessee, Lease, Description [Line Items]
Number of operating lease | Lease		2
Restricted cash balance		$ 50	$ 50
Weighted average incremental borrowing rate	4.75%
Operating lease cost		1,066	663
Operating lease, payments		492
Letter of Credit
Lessee, Lease, Description [Line Items]
Deposits			50
Office Building
Lessee, Lease, Description [Line Items]
Deposits		50
Restricted cash balance			150
Office Building | Letter of Credit
Lessee, Lease, Description [Line Items]
Operating lease deposit, letter of credit		150
Line of credit facility, annual step down of no defaults			200
Research and Development Expense
Lessee, Lease, Description [Line Items]
Operating lease cost		803	158
Selling, General and Administrative Expenses
Lessee, Lease, Description [Line Items]
Operating lease cost		$ 263	$ 505
Minimum | Facilities
Lessee, Lease, Description [Line Items]
Operating lease renewal periods		2 years
Maximum | Facilities
Lessee, Lease, Description [Line Items]
Operating lease renewal periods		5 years
Maximum | Facilities and Equipment
Lessee, Lease, Description [Line Items]
Operating lease term		12 months

LEASES Balance sheet Supplement

LEASES Balance sheet Supplemental (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Leases [Abstract]
Operating lease right-of-use assets	$ 2,496
Operating lease liabilities	2,059	$ 0
Total operating lease liabilities	$ 2,671

LEASES Weighted - Average Remai

LEASES Weighted - Average Remaining Lease Term (Details)	Dec. 31, 2019
Leases [Abstract]
Weighted average remaining lease term (years)	4 years 2 months 27 days
Weighted average discount rate (%)	475.00%

LEASES Operating Lease, Liabili

LEASES Operating Lease, Liability, Maturity (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Leases [Abstract]
2020	$ 726
2021	748
2022	557
2023	555
2024	376
Total minimum lease payments	2,962
Less: imputed interest	(291)
Total operating lease liabilities	$ 2,671
Operating Leases Maturity Prior to Adoption of ASU 942
2019		$ 658
2020		726
2021		748
2022		557
2023		555
2024		376
Future minimum obligations		$ 3,620

INCOME TAXES (Income Taxes by J

INCOME TAXES (Income Taxes by Jurisdiction) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
U.S. federal:
Current	$ 0	$ 0
Deferred	0	0
Total U.S. federal	0	0
U.S. state and local:
Current	1	2
Deferred	0	0
Total U.S. state and local	1	2
Foreign:
Current	0	0
Deferred	0	(1)
Total foreign	0	1
Income taxes differ from the amounts computed by applying the U.S. federal income tax rate to pretax income (loss) before income taxes
Expected income tax benefit	(6,284)	(5,211)
State income tax (benefit), net of federal benefit	(2,476)	(1,997)
Valuation allowance	9,131	7,372
Permanent differences:
Stock options	493	285
Research & development credit	(715)	(405)
Adjustment to deferred taxes	(157)	(68)
Foreign rate differential	1	2
Other	8	23
Provision for (benefit from) income taxes	$ 1	$ 1

INCOME TAXES (Deferred Tax Asse

INCOME TAXES (Deferred Tax Assets and Liabilities) (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
U.S. federal and state deferred tax liabilities—long term:
Right of use assets	$ 2,496,000
U.S. Federal and State
U.S. federal and state deferred tax assets—long term:
Accrued payroll	261,000	$ 102,000
Accrued expenses	77,000	45,000
Intangibles	390,000	418,000
Research & development credit	3,651,000	2,239,000
Net operating loss	27,568,000	20,140,000
Stock compensation	672,000	612,000
Lease liabilities	(750,000)	0
New jobs credit	8,000	8,000
Total long-term assets	33,377,000	23,564,000
Total deferred tax assets	33,377,000	23,564,000
U.S. federal and state deferred tax liabilities—long term:
Fixed assets	0	(16,000)
Deferred Tax Liabilities, Right-of-Use Assets	(701,000)	0
Total deferred tax liabilities	(701,000)	(16,000)
Deferred Income Tax Assets, Net	32,676,000	23,548,000
Less: Valuation allowance	(32,676,000)	(23,548,000)
Net deferred tax assets	0	0
Net operating loss	27,568,000	20,140,000
Foreign
U.S. federal and state deferred tax assets—long term:
Net operating loss	8,000	9,000
Total deferred tax assets	8,000	9,000
U.S. federal and state deferred tax liabilities—long term:
Less: Valuation allowance	(8,000)	(5,000)
Net deferred tax assets	0	0
Net operating loss	8,000	9,000
Intangibles	0	(4,000)
Net foreign deferred tax assets (liabilities)	$ 8,000	$ 5,000

INCOME TAXES (Narrative) (Detai

INCOME TAXES (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2019	Dec. 31, 2018
Operating Loss Carryforwards [Line Items]
Provision for (benefit from) income taxes		$ (1,000)	$ (1,000)
Tax Cuts and Jobs Act of 2017, Change in tax rate, income tax expense (benefit)	$ 6,100,000
Increase of valuation allowance		9,100,000	7,400,000
Federal net operating loss carryforwards		98,200,000
State net operating loss carryforwards		99,600,000
State and local income tax expense (benefit), continuing operations		1,000	2,000
Tax cuts and jobs act of 2017, federal net operating loss carryforwards		51,400,000
Interest
Penalties		0	0
Significant uncertain tax positions		0	$ 0
Switzerland
Operating Loss Carryforwards [Line Items]
Net operating loss		$ 51,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Purchase commitment amount	$ 824,000
Loss contingency accrual	0	$ 0
Loss in period	$ 0	$ 0

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - Consulting Agreement - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Aug. 31, 2019	Dec. 31, 2019
Related Party Transactions
Amounts of transaction	$ 50
Restricted stock units
Related Party Transactions
Expenses from transaction with related party	$ 100	$ 100
General and Administrative Expense
Related Party Transactions
Expenses from transaction with related party		21
Research and Development Expense
Related Party Transactions
Stock issued during period, value, restricted stock award, gross		$ 68

EMPLOYEE BENEFIT PLAN (Details)

EMPLOYEE BENEFIT PLAN (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
401(k) Savings Retirement Plan
Recorded plan matching contributions	$ 497	$ 372

SUBSEQUENT EVENTS Subsequent Ev

SUBSEQUENT EVENTS Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Thousands	Feb. 11, 2020	Feb. 06, 2020	Feb. 29, 2020	Dec. 31, 2019	Dec. 31, 2018
Subsequent Event [Line Items]
Common stock, par value (in dollars per share)				$ 0.001	$ 0.001
Sale of common stock, net of offering costs				$ 9,919	$ 21,189
Net proceeds from the sale of common stock from underwritten public offering				$ 0	$ 21,190
Subsequent Event
Subsequent Event [Line Items]
Sale of common stock, net of offering costs	$ 28,800
Net proceeds from the sale of common stock from underwritten public offering	$ 26,300		$ 26,300
Underwritten Public Offering | Subsequent Event
Subsequent Event [Line Items]
Stock issued during period (in shares)	19,166,667	16,666,667
Common stock, par value (in dollars per share)		$ 0.001
Share price (in dollars per share)		$ 1.50
Over-Allotment Option | Subsequent Event
Subsequent Event [Line Items]
Stock issued during period (in shares)	2,500,000	2,500,000

Uncategorized Items - resn-2019

Label	Element	Value
Restricted Cash, Current	us-gaap_RestrictedCashCurrent	$ 211,000
Restricted Cash, Current	us-gaap_RestrictedCashCurrent	150,000
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	64,000
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 64,000